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Abstract
CMV is the leading cause of both non-hereditary mental retardation and
hearing loss and CMV infection following transplantation carries a serious risk for
complications. The development of a CMV vaccine or better therapeutic
treatment is desired but to develop these a more complete understanding of
CMV pathogenesis is necessary. Sequence comparisons between attenuated
and virulent strains of HCMV map major differences to a 15kb region (ULb’)
containing the chemokine homolog, vCXCL-1. The vCXCL-1 protein of the
Toledo (Tol) strain was previously shown to function in vitro as a CXC
chemokine. Murine CMV (MCMV) also encodes a viral chemokine, MCK2. Prior
research has shown that infection of mice with a recombinant MCMV, RM4511,
which lacks a functional MCK2, resulted in decreased inflammation at the site of
infection and decreased dissemination to the salivary gland. Analysis of the role
of vCXCL-1 in the context of HCMV infection is limited by the species specificity
of the CMVs. One possible model system for analyzing the function of this
chemokine is the chimpanzee model of CMV infection. Chimpanzee CMV
(CCMV) has at least one gene with similarity to the vCXCL-1 gene of the Toledo
strain of HCMV. The hypothesis of this study was that vCXCL-1CCMV is a
functional CXC chemokine that contributes to viral dissemination. To address this
we initially compared the functional and biochemical characteristics in vitro of
vCXCL-1 from Toledo HCMV (vCXCL-1Tol) and CCMV (vCXCL-1CCMV) by
analyzing receptor binding, activation, chemotaxis, signaling, and anti apoptotic
suppression in neutrophils. The CCMV chemokine had a ~70-fold lower affinity
iv

for human CXCR2 compared to vCXCL-1Tol. Nevertheless, the homologs
functioned very similarly and we only observed differences in integrin induction
and the ability of the two chemokines to reduce neutrophil apoptosis. We
evaluated the in vivo function of vCXCL-1CCMV using MCMV infection in mice.
Due to the strict species specificity of CMV we used MCMV RM4511 to produce
recombinant MCMVs expressing vCXCL-1CCMV or a control host chemokine,
mCXCL1, under the control of the HCMV IE promoter. RMvCXCL1CCMV and
RMmCXCL1 grew with similar kinetics to RM4511 in cell culture and expressed
vCXCL-1CCMV

and

mCXCL1,

respectively.

Primary

dissemination

of

RMvCXCL1CCMV and RMmCXCL1 was similar to RM4511 but neither
recombinant was recovered from the salivary gland at any time point.
Maintenance of this phenotype in SCID mice showed the recombinant viruses
were not cleared from the salivary gland by the adaptive immune response.
RMvCXCL1CCMV and RMmCXCL1 were also not recovered in neutrophil-depleted
mice, although RM4511 titers were reduced in these mice indicating neutrophils
may play a role in dissemination of MCMV to the salivary gland. This study is the
first to characterize the CCMV viral chemokine, vCXCL-1, and show it is
functionally similar to vCXCL-1Tol. This provides evidence that the study of
vCXCL-1CCMV may contribute to a better understanding of its HCMV homolog.
Furthermore, this research is the first to evaluate the role of a CMV CXC
chemokine in vivo. Future work aimed at evaluating the role of other viral and
host chemokines in vivo using the mouse model will likely advance our
understanding of viral chemokines and their role in virus-host interactions.
v
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Chapter 1
Introduction

1

In the early 20th century researchers noted features characteristic of
cytomegalovirus (CMV) cytopathology in infants with what was later referred to
as cytomegalic inclusion disease (CID). However, CMV wasn’t determined to be
the etiologic agent of CID until three groups independently isolated the virus in
tissue culture in 1956 (Craig et al., 1957; Rowe et al., 1956; Smith, 1956). At
present, CMV is the most common congenitally acquired infection in the United
States and many other developed countries. Although the majority of these
infections are inapparent, symptomatic infections carry a high risk of central
nervous system (CNS) damage that can lead to long-term sequelae including
hearing loss and mental retardation. As a result, CMV is the leading cause of
both non-hereditary mental retardation and hearing loss. It is estimated as many
as 8000 children are born each year in the U.S. alone with CNS damage due to
congenital CMV infection (Arvin et al., 2004). Furthermore, up to 5% of
symptomatic infants die (Ross and Boppana, 2005).
Besides congenital infections, CMV is also considered one of the most
significant infectious diseases of immunocompromised individuals particularly
among transplant patients. Up to 50% of kidney recipients acquire a primary
CMV infection following transplantation and this carries a serious risk for
complications (Ho, 1991). However, perhaps the most severe outcomes occur in
bone marrow recipients who develop pneumonia that has a mortality rate
exceeding 80% (Ho, 2008).
Treatment of CMV related illness consists of a few antiviral agents such as
ganciclovir that inhibit the viral DNA polymerase. Although prophylactic use of
2

these drugs has contributed to a decline of CMV disease in immunocompromised
individuals, delayed onset of disease occurs in some patients following
completion of prophylactic treatment (Limaye et al., 2004). Administration of
these therapeutics can also result in organ toxicity and their long-term use is
associated with drug resistance (Coen, 2007). Furthermore, no treatment
regimen has to date been approved for cases of congenital infection (Edward S.
Mocarski, 2007).
A primary goal in the management of CMV is the implementation of a
vaccination program (Arvin et al., 2004). An example of vaccination for the
prevention of congenital infection is the rubella vaccine. This is routinely given as
part of the MMR vaccination regime. Rubella, a member of the paramyoxvirus
family, causes many of the same detrimental outcomes as CMV congenital
infection. Rubella was once the most common congenitally acquired viral
infection but the development of a rubella vaccine has led to the elimination of
this virus in the U.S (Plotkin, 2006). However, unlike rubella, for which a vaccine
was available just a few years following isolation of the virus, no vaccine against
CMV is currently available despite over three decades of effort.
A major obstacle in the design of a vaccine against CMV is the
complicated relationship between the virus and its host. CMV remains latent in
the host and although acute infection may be controlled, the virus is not
eliminated and can reactivate when the host’s immune system becomes
compromised. Additionally, the genome of CMV is large and contains numerous
genes involved in altering the host immune response during viral infection
3

(Banatvala and Brown, 2004). These include homologs of host proteins, such as
cytokine and chemokine receptors, and the focus of this thesis, chemokine
homologs (Alcami and Koszinowski, 2000). Evaluating the function of these viral
proteins will contribute to our understanding of CMV pathogenesis and provide
insight into the host immune response to viral infection that may ultimately
facilitate the development of an effective vaccine against CMV.

4

Chapter 2
Literature Review

5

Cytomegaloviruses
Genome and Structure
Cytomegaloviruses are classified within the -herpesvirus subfamily of
herpesviruses along with human herpesviruses 6 and 7. Characteristic features
of this virus subfamily include a narrow host range as well as slow growth in cell
culture (Edward S. Mocarski, 2001). Cytomegaloviruses infect a wide range of
hosts. These include the cytomegaloviruses of various primates such as human
(HCMV or human herpesvirus 5) and chimpanzee cytomegalovirus (CCMV) and
the muromegaloviruses that infect rodents such as murine cytomegalovirus
(MCMV) (Edward S. Mocarski, 2007).
As with all herpesviruses, the CMV genome is a linear, dsDNA molecule
that varies in size depending on the species. The genome of HCMV is
approximately 240 kilobase pairs (kbp) and is unusual among most CMVs in its
genome organization. The genome occurs as two main segments, the unique
long (UL) and unique short (US) regions that are flanked on both sides by inverted
repeats. Four different isomers of the genome can occur due to inversion of the
UL and US segments at the repeat junctions (Landolfo et al., 2003). Clinical
strains and the low passage lab strain, HCMVToledo, are missing a portion of the
internal repeat and instead contain an additional 15 kbp of DNA. CCMV is the
nearest relative to HCMV and has a similar genome size and configuration (Cha
et al., 1996). In contrast, the genome of MCMV occurs as a single unique
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sequence without internal repeats and only short direct repeats at the genome
termini (Ebeling et al., 1983).
The CMV genome is encapsidated within an icosahedral nucleocapsid.
The nucleocapsid is comprised of seven proteins, including the herpesvirusconserved major and minor capsid proteins (Edward S. Mocarski, 2001). The
capsid is surrounded by a protein-rich tegument layer that is enclosed within an
envelope membrane. Infectious virions contain at least thirty proteins, the
majority of which form the tegument layer. Tegument proteins serve various roles
and function in viral entry as well as modifying the host cell response upon virus
entry (Edward S. Mocarski, 2007). The surrounding envelope contains proteins of
both viral and cellular origin, the most abundant of which is the viral glycoprotein
B (gB), which is used for viral attachment and entry (Gibson, 1983).
DNA replication proceeds from the origin of replication, oriLyt (Hamzeh et
al., 1990). Expression of viral gene products is temporally regulated in a similar
manner to other herpesviruses and the genes are classified as immediate early,
early, and late genes. The major immediate early genes, IE1 and IE2 in HCMV,
are important transactivators of other viral gene products and transactivate early
and late genes. The early genes encode nonstructural proteins that contribute to
genome replication. Expression of late genes is dependent on viral replication
and encode the structural proteins and other proteins involved in virion assembly
(Edward S. Mocarski, 2001).
Human fibroblasts are permissive for HCMV and are commonly used in
cell culture, although a number of different cell types are permissive in vivo
7

including

endothelial

cells,

epithelial

cells,

smooth

muscle

cells,

and

macrophages (Pass, 2001; Sinzger et al., 1995). Entry into the host cell is
initiated by the association of gB with the proteoglycan, heparan sulfate, on the
cell surface (Compton, Nowlin, and Cooper, 1993). However, this interaction is
not sufficient for infection and interactions with additional host receptors are
needed for virus fusion and entry into the cell. Recently, epidermal growth factor
receptor

(EGFR) and members of the  integrin family have been found to

mediate virus entry although both receptors are not expressed on all permissive
cell types (Bentz and Yurochko, 2008; Feire, Koss, and Compton, 2004; Wang et
al., 2005; Wang et al., 2003). The tegument and nucleocapsid are released into
the cytoplasm and the nucleocapsid is transported to the nucleus where viral
replication occurs. Following replication of the genome and production of the
virion proteins, virion assembly occurs in the nucleus. Genome-length DNA
molecules

are

packaged

from

genome

concatemers

into

preformed

nucleocapsids. Virions acquire a primary envelope as they bud from the nuclear
membrane, which is subsequently shed, and the final envelope is obtained in the
golgi network (AuCoin et al., 2006). Nuclear and perinuclear inclusions,
characteristics of cytomegalovirus cytopathic effect (CPE), result from the
accumulation of nucleocapsids in the nucleus or golgi prior to release from the
cell. Mature virions are carried to the plasma membrane in endocytic vesicles
and released from the cell by exocytosis (Edward S. Mocarski, 2007).
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Epidemiology and Disease
The presence of HCMV in human populations is ubiquitous and rates of
infection can approach 100% particularly in developing countries or populations
of low socioeconomic status within developed countries (Pass, 1985; Staras et
al., 2006). Despite this frequency, CMV is not highly contagious and transmission
occurs following close contact with an infected individual shedding virus in bodily
fluids such as saliva or urine (Pass, 2001). A particularly important means of
transmission occurs among children and their caregivers, for instance in day care
centers, and is likely due to the prolonged shedding of virus in children as well as
the frequent contact with bodily fluids that occurs in this setting (Pass et al.,
1984). Day care workers show higher rates of infection compared to the
expected transmission rate in adults (Adler, 1989). CMV transmission is also
associated with sexual activity and is more prevalent among individuals with
multiple partners or those with sexually transmitted diseases (Chandler et al.,
1985; Pereira et al., 1990).
HCMV can also be transmitted vertically from mother to child via
postpartum, intrapartum, or transplacental transmission, the latter transmission
route being uncommon with other herpesviruses. Postpartum transmission of
CMV during breastfeeding is the most common route of transfer from mother to
child (Pass, 2001). Transmission is related in part to the duration of
breastfeeding with rates of infection increasing from 0% to 39% after just one
month of nursing. Additionally, more infants become infected when virus is
detectable in the breast milk (Dworsky et al., 1983). Intrapartum transmission
9

occurs in up to 50% of cases when virus is present in the genital tract during
delivery although shedding from this site occurs infrequently in women over the
age of 30 (Reynolds et al., 1973). Finally, CMV is also transferred by
transplacental infection of the fetus. From 20 to 40% of women who acquire a
primary CMV infection during pregnancy will transmit virus to their fetus.
Congenital infections also occur from viral reactivation during pregnancy but at a
considerably lower rate than primary infection (Pereira et al., 2005).
CMV is also a frequently encountered opportunistic pathogen in
immunocompromised individuals. All patients undergoing solid organ or
hematopoietic stem cell transplantation are at risk of complications from CMV
infection. Infection can be due to reactivation of latent CMV of the recipient or
transmission of CMV present in the transplanted organ (Landolfo et al., 2003).
Primary infection of a seronegative recipient typically carries the greatest risk for
severe disease. Importantly, the incidence of CMV disease in transplant patients
has declined due to improved screening of donor organs and blood products as
well as the effective use of antiviral drugs (Pereyra and Rubin, 2004). CMV has
also been a common problem in individuals with HIV or AIDS. As many as 20 –
40% of adults with AIDS developed CMV disease prior to the use of highly active
antiretroviral therapy (HAART) (Edward S. Mocarski, 2007). HAART treatment
preserves the immune function of those with HIV and has greatly reduced the
incidence of CMV disease in this group (Gerna et al., 1998). Nevertheless,
individuals with severe immune dysfunction due to AIDS are still at considerable
risk for complications from CMV infection.
10

Disease due to CMV varies in severity and primarily depends on the
immune status of the individual. CMV infection in the immunocompetent host is
largely asymptomatic (Stagno et al., 1986). However, mononucleosis develops in
some individuals and is the most common clinical outcome. Life-threatening
systemic infections rarely occur (Edward S. Mocarski, 2007). CMV disease in the
newborn depends largely on the route of transmission. While peri- or postpartum
transmission is generally inapparent, congenital infection can result in serious
outcomes. Primary infection during pregnancy carries the greatest risk for
symptomatic disease in the newborn and can result in permanent defects such
as mental retardation, and hearing or vision loss (Revello and Gerna, 2002).
Likewise, CMV infection in the immunocompromised host can have severe
consequences. CMV in solid organ transplant recipients can result in systemic
disease and increases the likelihood of organ rejection. CMV infection has also
been associated with an increased risk of coronary artery disease in heart
transplant patients (Grattan et al., 1989). Hematopoietic stem cell recipients
infected with CMV frequently present with pneumonitis or gastritis (Ljungman,
1996). CMV is also associated with an increased risk for opportunistic infections
in both transplant groups (Ljungman, Griffiths, and Paya, 2002). CMV disease in
individuals with HIV manifests most often as retinitis (Cheung and Teich, 1999).
Furthermore, an association between CMV and the progression of HIV infection
has been suggested although definitive evidence identifying HCMV as a risk
factor is still lacking (Pass, 2001).

11

Dissemination
HCMV is acquired naturally through infection of the genitourinary and
respiratory tracts where it replicates efficiently within epithelial cells at these
sites. The process whereby HCMV disseminates to other organs from the initial
site of infection is incompletely understood but is thought to occur following a
viremic stage (i.e. virus present in the blood).

The current model of HCMV

dissemination is based in part on studies of MCMV. Dissemination of MCMV
occurs by a biphasic viremia, initially seeding organs such as the liver and spleen
followed by a secondary viremia seeding the salivary glands (Collins, Quirk, and
Jordan, 1994). This dissemination is exclusively cell associated. Whether HCMV
viremia is temporally regulated in this manner is unknown.
Evidence of the mechanism of HCMV dissemination is implied from
clinical data. Clinical observations provided early evidence for the transmission of
CMV via the bloodstream. It is well established that seronegative individuals can
acquire CMV following blood transfusions from seropositive donors (Meyers,
Flournoy, and Thomas, 1986). Depletion of leukocytes from seropositive blood
markedly decreases the incidence of such infections (Bowden et al., 1995;
Gilbert et al., 1989). These findings and the inability to detect free virus within the
blood even during acute infection indicate the virus is cell-associated (Howell,
Miller, and Martin, 1979; Rinaldo, Black, and Hirsch, 1977). In individuals with
detectable viremia, HCMV is most often isolated from neutrophils and monocytes
(Gerna, Baldanti, and Revello, 2004). Viral DNA can be detected in both cell
populations although DNA levels are often higher in neutrophils than monocytes.
12

Likewise, infectious virus is isolated more often from neutrophils (Dankner et al.,
1990; Saltzman, Quirk, and Jordan, 1988). Rat cytomegalovirus (RCMV) and
MCMV have been detected in these cell types as well, although recovery of
MCMV is highest in monocytes rather than neutrophils (Bale and O'Neil, 1989;
Collins, Quirk, and Jordan, 1994; Stoddart et al., 1994; van der Strate et al.,
2003). The detection of HCMV DNA (DNAemia) or the viral structural protein,
pp65, (antigenemia) in neutrophils is considered diagnostic of viremia (Boivin et
al., 1998; Gerna et al., 1990; Grazia Revello et al., 1989). Despite a clear
association of CMV with neutrophils during acute infection, an inability to detect
viral DNA in neutrophils of healthy, seropositive individuals suggests CMV does
not persist in these cells (Taylor-Wiedeman et al., 1993). In contrast, the
presence of viral DNA in monocytes and myelomonocytic progenitor cells of
healthy subjects has been demonstrated (Kondo, Xu, and Mocarski, 1996;
Taylor-Wiedeman et al., 1991; von Laer et al., 1995a). Additionally, virus can be
recovered from these cell types following prolonged cocultivation in vitro with
permissive cell monolayers. These assays have led to the conclusion that
monocytes and their progenitors are the likely reservoirs for latent CMV (Kondo,
Kaneshima, and Mocarski, 1994). Again demonstrating the similarities between
MCMV and HCMV, MCMV has been identified in macrophages and bone marrow
progenitor cells of latently infected mice (Koffron et al., 1998; Mitchell, Leung,
and Stevens, 1996; Pollock et al., 1997).
Viral replication in neutrophils is generally considered abortive with
transcription confined to immediate early genes (Grefte et al., 1994; Sinzger et
13

al., 1995). However, results have been inconsistent with some groups also
reporting the detection of early and late viral transcripts (Dankner et al., 1990;
von Laer et al., 1995b). A decrease in IE transcripts was found when HCMVinfected neutrophils were treated with transcriptional and translational inhibitors,
while no change was noted in late gene products consistent with active
transcription of only the IE genes. It was suggested neutrophils acquire early and
late transcripts by direct transmission from infected cells permissive for
replication or from phagocytosis of such cells (Gerna et al., 2000). In spite of its
inability to replicate HCMV, neutrophils isolated from viremic individuals are able
to transmit infectious virus. Thus neutrophils may have a role in disseminating
HCMV (Gerna et al., 1990; Saltzman, Quirk, and Jordan, 1988).
Like neutrophils, infection of monocytes leads to abortive replication, but
upon their differentiation into macrophages these cells become permissive
(Gerna et al., 1992; Grefte et al., 1994; Ibanez et al., 1991; Taylor-Wiedeman,
Sissons, and Sinclair, 1994; Zhuravskaya et al., 1997). One group found that
HCMV infection of monocytes induced their differentiation into macrophages
(Smith et al., 2004). Therefore, migration of infected monocytes into tissues and
their subsequent differentiation into macrophages could support viral replication
at these sites and CMV may promote this process.
How neutrophils and monocytes acquire HCMV is controversial. An early
report of a patient with fatal CMV disease identified CMV virions in the
phagosomes of neutrophils (Martin et al., 1984). However, no other group has
reported similar findings. In vitro studies have shown uptake of free virus by
14

neutrophils is minimal suggesting phagocytosis is not likely the main source of
CMV present in neutrophils (Grundy et al., 1998). Rather, transmission of CMV to
neutrophils as well as monocytes is thought to primarily occur following direct
contact with infected cells (Digel et al., 2006). Endothelial cells are a natural site
of CMV infection in vivo and may facilitate dissemination of CMV via neutrophils
or monocytes (Fish et al., 1995; Jarvis and Nelson, 2002; Sinzger et al., 1995). In
vitro, CMV-infected endothelial cell monolayers were found to transmit virus to
neutrophils following co-culture or transmigration assays. Subsequent transfer of
CMV from the infected neutrophils to fibroblast monolayers indicated the
presence of infectious virions (Gerna et al., 2000; Grundy et al., 1998). Similar
findings have been reported following co-culture of monocytes with infected
endothelial cells (Bentz et al., 2006; Waldman et al., 1995). Furthermore, both
neutrophils and monocytes exhibit enhanced migration across endothelial cells
infected with CMV (Bentz et al., 2006; Craigen et al., 1997). Expression of the
chemokine, CXCL8, is upregulated in CMV-infected endothelial cells and could
recruit neutrophils to the site of infection (Grundy et al., 1998). Additionally,
HCMV encodes a chemokine homolog, vCXCL-1, able to induce migration of
neutrophils in vitro (Penfold et al., 1999). Similarly, the MCMV chemokine
homolog, MCK2, was found to augment viremia and the recruitment of monocytic
progenitor cells to the site of infection (Fleming et al., 1999; Saederup et al.,
2001).
Collectively these data have led to a proposed model of CMV
dissemination from the infected mucosa. CMV at the epithelial surface initially
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spreads to the endothelium. Infected endothelial cells recruit leukocytes,
particularly neutrophils and monocytes, and this may be facilitated or enhanced
by virally encoded chemokines. Neutrophils and monocytes acquire infectious
CMV upon contact with infected endothelial cells. These cells then disseminate
the virus through the bloodstream and can migrate across the endothelium
seeding various tissues (Figure 1). During transmigration, the differentiation of
monocytes into the permissive macrophage could further enhance the replication
of CMV within the tissues. In addition to being a model for viral dissemination
during acute infection, this model offers an explanation for dissemination of
reactivated CMV present in monocytes or monocyte progenitor cells (Grundy et
al., 1998; Pass, 2001; Smith et al., 2004).

Chemokines and Chemokine Receptors
Chemokines
Chemokines are small chemotactic cytokines produced by leukocytes and
other cells that typically range in size from 9-130 amino acids. The first
chemokine to be identified was CXCL4 (previously platelet factor 4) an
angiostatic chemokine stored in the  granules of platelets (Walz et al., 1977).
However, it wasn’t until the discovery of CXCL8 (IL-8) in 1987 that this class of
proteins was found to have chemotactic properties (Schroder et al., 1987). To
date approximately 50 human chemokines have been identified (Table 1).
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(B)

CXCL8

(A)

Figure 1. Proposed model of CMV dissemination. The infected epithelium
transmits CMV (·) to endothelial cells (EC). Leukocytes, including neutrophils (N)
and monocytes, are recruited by host (such as CXCL8) or viral chemokines
secreted by ECs. Infected ECs (black cells) transmit CMV via direct contact with
these cells. Infected leukocytes then disseminate CMV via the bloodstream (A) or
through transmigration into the tissues (B) (adapted from Grundy, 1998).
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Table 1. The known human chemokine receptors and some of their ligands
(adapted from Rossi and Zlotnik, 2000).
Chemokine Receptors

Human Chemokine Ligands

CXCR1

CXCL8, CXCL6

CXCR2

CXCL8, CXCL6, CXCL1, CXCL2, CXCL3, CXCL5

CXCR3

CXCL9, CXCL10, CXCL11

CXCR4

CXCL12

CXCR5

CXCL13

CCR1

CCL3, CCL4, CCL5, CCL14, CCL15, CCL16

CCR2

CCL2, CCL8, CCL7, CCL13

CCR3

CCL11, CCL24, CCL7

CCR4

CCL17, CCL22, CCL3, CCL5

CCR5

CCL3, CCL4, CCL5

CCR6

CCL20

CCR7

CCL19, CCL21

CCR8

CCL1

CCR9

CCL25

CCR10

CCL27, CCL28

XCR1

XCL1, XCL2

CX3CR1

CX3CL1
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Chemokines are divided into four main groups based on the spacing of
their conserved cysteine residues. The two largest groups, the CC and CXC
chemokines, are so named because the two conserved amino terminal cysteines
are either adjacent (CC) or separated by an intervening amino acid (CXC)
(Baggiolini, 1998). CXC chemokines can be further subdivided into ELR (+) or (-)
dependent upon the presence of a glutamate-leucine-arginine motif directly
preceding the CXC motif. ELR CXC chemokines, such as CXCL8 and CXCL1
(Gro), primarily attract neutrophils, although some members of this group also
have angiogenic properties through their recruitment of endothelial cells (Strieter
et al., 1995a). In contrast, many non ELR CXC chemokines are angiostatic and
almost exclusively attract cells other than neutrophils. The CC chemokines are
the largest group and attract a variety of cell types including monocytes,
basophils, eosinophils, and dendritic cells (Murphy, 2003). The third chemokine
class, CX3C, has three amino acids separating the first two cysteines and has
only one member, CX3CL1 or fractalkine (Bazan et al., 1997). Fractalkine, as well
as CXCL16, are unique in that the chemokine domain of these proteins is linked
to a mucin-like stalk that anchors the chemokine to the cell membrane through its
transmembrane region. CX3CL1 can also be enzymatically cleaved from the
membrane and function as a soluble factor (Charo and Ransohoff, 2006). Lastly,
XCL1 and 2 (lymphotactin  and ) are the sole members of the C chemokine
group and contain only two cysteines (Kelner et al., 1994).
Chemokines are important in the regulation of a number of biological
processes, the most well known being chemotaxis. Chemokine gradients provide
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for the directed movement of cells through the blood or tissues. Although
chemokines are secreted, they can bind glycosaminoglycans (GAGs) such as
heparan sulfate present on the cell surface or within the extracellular matrix
creating a solid support for gradient formation as well as receptor interactions
(Huber et al., 1991; Webb, Clark-Lewis, and Alcami, 2003). In one experiment,
mutants of CCL2, CCL4, and CCL5 that inefficiently bind GAGs induced
chemotaxis in vitro but recruited far fewer cells compared to wild type
chemokines when injected into the peritoneum of mice, highlighting the
importance of the chemokine-GAG interaction in vivo (Proudfoot et al., 2003).
Chemokines also promote cell migration through their effect on leukocyte
adhesion molecules, such as the 2-integrins, CD11a, b, and c. Activated 2integrins bind their ligands on endothelial cells resulting in “tight binding” of the
two cells, a crucial step in the transmigration of leukocytes into tissues (Ley et al.,
2007). Chemokine-mediated “inside-out” signaling induces conformation changes
in the 2-integrins allowing the high affinity ligand binding needed for cell arrest
(Laudanna et al., 2002). Additionally, chemokines such as CXCL8 have been
found to upregulate the expression of 2-integrins on cells such as neutrophils
(Springer, 1994). The importance of chemokines in orchestrating cell trafficking
during inflammation is well established. Microbial products and inflammatory
cytokines like TNF induce the expression of chemokines and their receptors to
initiate the inflammatory response (Baggiolini, 2001). However, it has become
increasingly clear chemokines are necessary for efficient homing of leukocytes
during homeostasis. For instance, the migration of T cells to secondary lymphoid
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tissues depends on CCL19 and CCL21 and B cell migration is regulated by
CXCL12 (von Andrian and Mempel, 2003).
In addition to cellular trafficking, chemokines promote the effector
functions of cells. Cellular activation in response to chemokines can cause the
exocytosis of granules containing a host of preformed mediators, which may
amplify the inflammatory response (Bokoch, 1995). In neutrophils, these
mediators include antimicrobial proteins such as defensins and lysozyme as well
as proteases capable of degrading proteins of the extracellular matrix and
basement membrane (Witko-Sarsat et al., 2000). Chemokines may also trigger
the formation of reactive oxygen species, oxygen metabolites with potent
antimicrobial activities. Initiation of this “respiratory burst” occurs upon assembly
of the enzyme NADPH oxidase. NADPH oxidase catalyzes the formation of the
unstable superoxide anion, which reacts to produce additional microbicidal
molecules (Baggiolini et al., 1993).
Chemokine Receptors
Chemokines bind and signal via receptors of the seven transmembrane G
protein coupled receptor (GPCR) family. Chemokine receptors are classified
according to the chemokine class with which they interact. Therefore, CXC
chemokines bind CXC receptors and so forth. Chemokine receptors typically bind
multiple ligands and thus there are far fewer receptors than chemokines (Murphy,
2002).

These

receptors

have

cytoplasmic

domains

that

interact

with

heterotrimeric G proteins consisting of , , and  subunits. Conformational
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changes in the receptor upon chemokine binding result in its interaction with a
GDP bound G protein. The receptor functions as a guanine nucleotide exchange
factor (GEF), facilitating the exchange of GDP for GTP. This results in the
dissociation of the G and G subunits. Both subunits can mediate downstream
signaling events (Ben-Baruch, Michiel, and Oppenheim, 1995; Gether, 2000).
Following chemokine receptor activation, the G subunit regulates a
number

of

signaling

pathways.

G

mediates

the

phosphorylation

of

phospholipase C (PLC). Activated PLC hydrolyzes phosphotidylinositol 4,5bisphosphate (PIP2) to produce inositol triphosphate (IP3) and diacylglycerol
(DAG). IP3 triggers the transient release of Ca2+ from the endoplasmic reticulum
into the cytoplasm, which is frequently used as a marker of cellular activation.
DAG activates members of the protein kinase C (PKC) family (Murdoch and Finn,
2000). PKC activation enhances ROS production and has been shown to
upregulate CD11b/CD18 in neutrophils (Takami, Terry, and Petruzzelli, 2002).
The G subunit also initiates phosphotidylinositol 3-kinase (PI3K) activity. PI3K
phosphorylates PIP2 generating phosphotidylinositol 3,4,5-triphosphate (PIP3).
PIP3 accumulation at the leading edge of neutrophils confers polarity and is
important for chemotaxis (Weiner et al., 2002). Nevertheless, other pathways are
likely important for chemotaxis as the migration of cells isolated from PI3K knockout mice is impaired although not completely eliminated. PIP3 also recruits
additional effectors to the plasma membrane such as protein kinase B (PKB or
Akt) (Mellado et al., 2001). Akt induces anti-apoptotic mechanisms that promote
cell survival, although the ultimate fate of the cell is determined by input from
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multiple pathways (Mayadas and Cullere, 2005; Vlahakis et al., 2002). MAP
kinase (MAPK) activity is also stimulated upon receptor signaling. In transfected
Cos-7 cells, Gi subunits were unable to stimulate MAPK consistent with a role
for G in activating this pathway (Koch et al., 1994). In particular, PI3K can
phosphorylate the small G protein, Ras, which subsequently initiates the MAPK
pathway by binding to the MAPKKK, Raf. Like Akt, activation of the MAPKs, ERK
1 and 2, generates signals that protect the cell from apoptosis (Bokoch, 1995;
Vlahakis et al., 2002). Additionally, ERK1/2 stimulate integrin-dependent
adhesion of cells following chemokine activation (Takami, Terry, and Petruzzelli,
2002).
The G subunit has GTPase activity and can hydrolyze GTP to GDP
resulting in the reassociation of the G and G subunits and termination of the
signal. Additionally, G protein receptor kinases (GRKs) may phosphorylate serine
and threonine residues in the c-terminus of the receptor to which  arrestins may
bind.  arrestins prevent association of the G protein with the receptor leaving the
receptor refractory to subsequent stimulation. Additionally,  arrestins can
coordinate receptor internalization. This results in the degradation of the receptor
or dephosphorylation and recycling of the receptor to the cell surface (Neel et al.,
2005). Recently,  arrestins have also been shown to act as adaptor proteins
capable of mediating signaling events downstream of the chemokine receptor
(Lefkowitz and Shenoy, 2005).
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Receptor signaling requires the interaction of the receptor with multiple
motifs present on the chemokine. Residues in the N-loop, a region that follows
the first two cysteines, mediate chemokine binding and can determine receptor
specificity (Fernandez and Lolis, 2002). For instance, when portions of the Nloops of CXCL8 or CXCL1 were interchanged these chemokines showed a
reverse in their patterns of receptor binding and specificity (Lowman et al., 1996).
In addition, activation of the receptor requires residues in the N-terminus of the
chemokine. In the case of CXCL12, truncation of the first amino-terminal residue
is sufficient to produce a receptor antagonist (Crump et al., 1997). Alternatively, a
CCL5 antagonist was generated by the extension of the N-terminus by a single
amino acid (Proudfoot et al., 1996). The ELR motif preceding the first cysteine in
certain CXC chemokines is another important determinant of receptor activation
and mutation of these residues impairs the ability of these chemokines to bind
and stimulate their receptors (Clark-Lewis et al., 1991; Hebert, Vitangcol, and
Baker, 1991; Schraufstatter et al., 1993). Nevertheless, other regions within the
chemokine also contribute to receptor interactions as synthetic peptides
comprising the N-terminus and the N-loop have reduced activities compared to
their full-length counterparts (Baggiolini, Dewald, and Moser, 1997).

Viral Chemokine Homologs
HCMV encodes two ORFS with homology to CXC chemokines, UL146
and UL147 (Cha et al., 1996). Chimpanzee CMV encodes homologs of UL146
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and UL147 as well as the related gene UL146a. While no functional data is
available for UL147, analysis of the protein product of HCMV UL146, vCXCL-1,
demonstrated its capacity as a functional chemokine. vCXCL-1 was shown to
bind exclusively to hCXCR2 with an affinity similar to that of the host chemokine,
CXCL8. Additionally, vCXCL-1 was able to induce chemotaxis and intracellular
calcium release in human neutrophils, again to levels comparable to host
chemokines (Penfold et al., 1999). The function of the HCMV vCXCL-1 in vitro
suggests the potential for this viral chemokine to alter the response of neutrophils
in the course of CMV infection. A mutant HCMV virus with a deletion of UL146UL147 was not transmitted to neutrophils but retained its tropism for other cell
types providing additional evidence these proteins facilitate an interaction of CMV
with neutrophils (Hahn et al., 2004).
Due to the strict species specificity of CMV, in vivo characterization of
UL146 and UL147 has been limited to sequence analysis of clinical HCMV
isolates. UL146 is highly variable, differing as much as 60% among isolates (Heo
et al., 2008). It was postulated that this variability might correlate with the severity
of CMV disease however no clear relationship in this regard has been identified
(Arav-Boger, Zong, and Foster, 2005; Bale et al., 2001; Hassan-Walker et al.,
2004).
HCMV also encodes genes with limited homology to CC chemokines.
UL128 and UL130 both have signal sequences and conserved cysteine motifs
similar to CC chemokines (Akter et al., 2003). It has yet to be determined
whether these proteins function as chemokines. Interestingly, the UL128-131
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locus was found to be necessary for endothelial cell and leukocyte tropism based
on the inability of HCMV UL128-131 deletion mutants to infect these cell types
(Hahn et al., 2004). This likely explains the loss of endothelial cell tropism in labadapted strains of HCMV, a number of which were shown to have deletions or
mutations in at least one gene from this region (Akter et al., 2003). The UL128131 proteins have recently been shown to interact with gH/gL complexes that
mediate entry of CMV into endothelial and epithelial cells, in contrast to the
gH/gL/gO complexes that mediate virus entry into fibroblasts (Wang and Shenk,
2005a; Wang and Shenk, 2005b).
The best characterized of the CMV chemokines is the CC chemokine
homolog of MCMV. Originally identified as the M131 gene product, MCK1, it was
soon determined that the transcript present during MCMV infection is a spliced
product of M131 and M129, referred to as MCK2. The CC chemokine domain is
confined to the region coded by MCK1 and is followed by a long carboxy-terminal
domain with no known homology, making MCK2 considerably longer than other
chemokines (MacDonald et al., 1999; MacDonald, Li, and Virgin, 1997).
Initial studies in vitro showed MCK1 induced higher levels of Ca2+
mobilization in peritoneal exudates cells from mice infected with MCMV than cells
from uninfected mice demonstrating MCK1 could activate cells recruited to the
site of infection (Saederup et al., 1999). MCK2 was demonstrated to be important
for viral spread within the host when a recombinant MCMV with mutations in the
m131 gene showed a defect in dissemination. Mice infected with this mutant
developed less inflammation at the site of inoculation, reduced secondary
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viremia, as well as lower viral titers in the salivary glands, a site of dissemination
following secondary viremia (Fleming et al., 1999; Saederup et al., 2001). This
was the first direct evidence that a CMV encoded chemokine is important for the
dissemination of the virus in its host. Additional work identified the cell type
recruited by MCK2 as a late myeloid progenitor, consistent with reports that CMV
infects and can remain latent in cells of the myelomonocytic lineage (Noda et al.,
2006).
Rat CMV (RCMV) encodes a CC chemokine with similarity to both M131
and M129, having N-terminal chemokine homology and a long carboxy-terminus
like that of MCK2 (Vink, Beuken, and Bruggeman, 2000). Rats infected with
RCMV deletion mutants lacking r131 had reduced viral loads in the spleen and
salivary glands. Additionally these mice had reduced swelling and macrophage
infiltration at the site of virus inoculation (Kaptein et al., 2004). Therefore, pr131
appears to be a functional homolog of MCK2.
Guinea pig CMV (GPCMV) has one gene with homology to CC
chemokines, though it lacks positional or sequence similarity to the m131/m129
genes of MCMV. GPCMV-MIP was most similar to the cellular chemokines, MIP1/ and HCC-1. GPCMV-MIP induced Ca2+ flux and migration of cells
expressing HCCR-1 but did not elicit a response from cells expressing other CC
receptors. HCC-1 is known to increase the proliferation of monocyte progenitors,
a cell type infected by HCMV, and thus GPCMV-MIP is predicted to enhance the
proliferation and/or recruitment of permissive cells consistent with the role of
MCK2 (Haggerty and Schleiss, 2002).
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Another -herpesvirus, human herpesvirus 6 (HHV-6), encodes a
chemokine homolog, U83 (or vCCL4), which may facilitate viral dissemination in
a manner similar to MCK2. U83 has a unique CX2CC motif but functions as a CC
chemokine (French et al., 1999; Gompels et al., 1995). At least two HHV-6
strains exist, HHV-6 variant A and HHV-6 variant B and each encodes a U83
gene (U83A and U83B, respectively) (French et al., 1999). U83B is a selective
CCR2 agonist, inducing calcium mobilization and chemotaxis of THP-1 cells and
CCR2 transfectants albeit with lower activity than the cellular chemokine
RANTES (Luttichau et al., 2003; Zou et al., 1999). This may be due in part to the
extended N-terminus of U83B, which is associated with the reduced activity of
some chemokine mutants (Fernandez and Lolis, 2002). HHV-6 replicates in CD4
T cells and can establish latency in monocytes, both cells types that express
CCR2 (Lusso et al., 1988). Therefore, U83 may recruit cells important for the
establishment of acute and latent HHV-6 infection. In contrast, U83A induces flux
in cells expressing a number of CC receptors making it the only known broadly
acting CC agonist encoded by a virus. Interestingly, HHV-6A shows greater
dissemination within the host than HHV-6B and it was suggested this might relate
to the ability of U83A to interact with additional host cell types compared to U83B
(Dewin, Catusse, and Gompels, 2006).
Kaposi’s

sarcoma-associated

herpesvirus

(KSHV)

is

a

gamma

herpesvirus responsible for the development of Kaposi’s sarcoma (KS), an
endothelial cell-derived tumor that occurs in immunocompromised individuals.
KSHV encodes three CC chemokine homologs, vCCL1, 2, and 3 (vMIP1-3).
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vCCL1 and vCCL2 have similarity to CCL1 and the more distantly related vCCL3
is most similar to CCL11 (eotaxin) (Neipel, Albrecht, and Fleckenstein, 1997;
Nicholas et al., 1997; Stine et al., 2000). While MCK2 enhances the inflammatory
response to MCMV to facilitate viral dissemination, evidence suggests the KSHV
chemokine homologs may contribute to viral pathogenesis by impairing the
immune response to KSHV, thus interfering with its clearance. vCCL1 is an
agonist of CCR8, a chemokine receptor expressed on TH2 cells, and stimulates
Ca2+ flux of CCR8 expressing cell lines and isolated T cells (Dairaghi et al., 1999;
Endres et al., 1999; Nicholas et al., 1997). vCCL3 functions via XCR1 and CCR4
and can induce chemotaxis of TH2 cells, which differentially express CCR4
(Luttichau et al., 2007). In contrast, vCCL3 is a poor chemoattractant of TH1 cells
(Stine et al., 2000). Like the other KSHV chemokines, vCCL2 signals via
receptors present on TH2 cells, CCR8 and CCR3 (Sozzani et al., 1998; Weber et
al., 2001). However, vCCL2 is unique in that it also blocks receptors of all known
chemokine classes, many of which are found on TH1 cells (Kledal et al., 1997).
Consistent with a broadly acting antagonist, administration of vCCL2 impairs the
recruitment of leukocytes in both the rat glomerulonephritis and lymphocytic
choriomeningitis virus models of inflammation (Chen et al., 1998; Lindow et al.,
2003). Although vCCL1-3 have not been studied in animal models in the context
of KSHV infection, collectively the data to date suggests these chemokines may
alter the immune response to KSHV producing a TH2 polarized response that
may be inefficient in clearing the virus. In fact, KSHV lesions expressing vCCL2
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have a predominance of TH2 polarized cells compared to TH1 type cells based on
cytokine profiles within the lesion (Weber et al., 2001).
The KSHV chemokines may also contribute to KSHV pathology via other
mechanisms. All three chemokines induce angiogenesis, a feature commons to
KS. This may be due in part to their ability to chemoattract endothelial cells
(Boshoff et al., 1997; Haque et al., 2001; Stine et al., 2000). Furthermore, vCCL1
and 2 have anti-apoptotic effects in cell culture. Infected cells also exhibited
higher levels of viral replication possibility due to the prolonged lifespan of the
cells (Choi and Nicholas, 2008).
In addition to herpesviruses, poxviruses also produce viral chemokines.
Molloscum contagiosum virus (MCV) is a poxvirus that causes benign tumors in
children as well as opportunistic infections in immunocompromised individuals.
Interestingly, these lesions lack inflammatory infiltrates and it is thought virally
encoded factors, such as the CC chemokine homolog, MC148, might contribute
to the feature of these lesions. Sequence analysis predicted MC148 to be an
antagonist because the N-terminus of the protein, a region important for receptor
activation, is shorter compared to cellular CC chemokines. In vitro analysis
confirmed this hypothesis. MC148 inhibits the migration of monocytes,
lymphocytes, and neutrophils in response to a range of chemokines and was not
an agonist for any CC or CXC receptor tested (Bugert et al., 1998; Damon,
Murphy, and Moss, 1998). The number of receptors that MC148 antagonizes
was narrowed to only CCR8 after further studies (Luttichau, Gerstoft, and
Schwartz, 2001; Luttichau et al., 2000). In vivo analysis of MC148 is limited
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because appropriate cell culture or animal models for the study of MCV are
lacking. These examples show the wide range of viral chemokines that can affect
the viral life cycle.

Summary and Statement of Research Aims
Due to the potential for serious outcomes in human cytomegalovirus
infected newborns and immunocompromised individuals, the development of a
CMV vaccine or other effective therapeutic treatment is desired.

In order to

develop these treatments, a more complete understanding of CMV pathogenesis,
including viral dissemination, is needed. CMV dissemination occurs via cellassociated viremia in cells of hematopoietic origin including monocytes and
neutrophils. However, the relative contribution of the different cell types to virus
spread is not clearly defined. Furthermore, many CMVs encode chemokine
homologs that alter the response of leukocytes during viral infection. The CC
chemokines encoded by MCMV and RCMV, MCK2 and pr131 respectively,
induce inflammatory responses that enhance virus dissemination to the salivary
gland in vivo. The HCMV gene UL146 encodes a CXC chemokine, vCXCL-1,
that functions comparably to CXCL8 in vitro. The analysis of this protein’s role in
the context of HCMV infection is limited by the species specificity of the CMVs.
Chimpanzee cytomegalovirus is the closest relative to HCMV and encodes a
homolog of HCMV UL146, although their primary amino acid sequences vary.
Nevertheless, CCMV may be an appropriate model for analyzing the function of
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vCXCL-1 in vivo. Additionally, CCMV vCXCL-1 may be a functional homolog of
the cytomegalovirus CC chemokines, such as MCK2, and facilitate dissemination
of CCMV. The hypothesis of this study is that vCXCL-1CCMV is a functional CXC
chemokine that contributes to viral dissemination. To test this hypothesis, the
following research objectives were performed:
1. Express CCMV vCXCL-1 and evaluate its function as a
chemokine in vitro.
2. Use MCMV as a surrogate to generate a recombinant MCMV
expressing vCXCL-1CCMV to determine its ability to facilitate viral
dissemination in mice.
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Chapter 3
Functional Characterization of Chimpanzee Cytomegalovirus
Chemokine, vCXCL-1CCMV
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This chapter is a publication by the same name published in the Journal
Virology in 2007 by Mindy Miller-Kittrell, Jiqing Sai, Ann Richmond, and Tim E.
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primary contributions to this paper include (1) the majority of the lab work and (2)
most of the data analysis, and (3) most of the writing of this paper.

Abstract
Human

cytomegaloviruses

(HCMVs)

are

important

pathogens

in

immunocompromised patients and newborns. The viral chemokine, vCXCL-1, of
the Toledo (Tol) strain of HCMV has been implicated in HCMV virulence.
Chimpanzee CMV (CCMV) has several genes with similarity to the vCXCL-1TOl
gene, UL146. In order to test whether the CCMV viral chemokine, vCXCL-1CCMV,
is similar to vCXCL-1Tol, we characterized its function in vitro. Receptor binding,
activation, chemotaxis, signaling, and apoptosis in neutrophils were compared
between vCXCL-1Tol and vCXCL-1CCMV and host chemokines. Although the
homologues have similar activation potentials, chemotactic properties, and
signaling, vCXCL-1CCMV had a ~70-fold lower affinity for CXCR2 and displayed
differences in integrin upregulation and neutrophil apoptosis.
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These data

demonstrate that in spite of extensive amino acid variability in vCXCL-1, CCMV
may provide a model for assessing the role of vCXCL-1 in CMV pathogenesis in
vivo.

Introduction
Human cytomegalovirus (HCMV) is a ubiquitous -herpesvirus, infecting
between 50-90% of the population (Pass, 1985). Although asymptomatic in most
cases, HCMV can cause serious complications in immunocompromised patients
and newborns. Reactivation of latent HCMV or primary HCMV infection increases
graft versus host disease (McCarthy et al., 1992), organ rejection in transplant
patients (Ljungman, 1996), and inflammatory diseases such as gastroenteritis
and retinitis in AIDS patients (Cheung and Teich, 1999). Congenital HCMV
infection is the leading cause of infectious hearing loss in infants (Pass, 2001)
and can lead to long-term sequelae such as learning disabilities and mental
retardation. Due to the life-long effects associated with CMV congenital
infections, the Institute of Medicine lists the development of a CMV vaccine as
one of its top five priorities (Arvin et al., 2004). In an effort to develop a safe and
effective vaccine, a more thorough understanding of HCMV pathogenesis is
needed.
HCMV has a number of genes that encode proteins capable of
suppressing or modulating the immune system that have been implicated in
pathogenesis (Mocarski, 2002; Wiertz et al., 1997). Every aspect of the immune
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response can be altered including class I and class II antigen processing and
presentation as well as inflammatory responses (Mocarski, 2002). Proteins that
alter immune responses likely contribute to HCMV’s pathogenesis. Therefore
understanding HCMV immune modulators may aid in designing safe and
effective vaccines or potential antiviral therapeutics.
The Toledo strain of HCMV, a strain that is known to cause disease in
humans (Quinnan et al., 1984), was shown to produce a functional viral
chemokine, vCXCL-1 (Penfold et al., 1999). Although chemokines are divided
into four families, the majority of chemokines fall into the two families, CC and
CXC chemokines, based on the spacing of their amino terminal cysteines. The
CXC family has an additional amino acid between the two cysteines. The
presence of a glutamate, leucine, arginine (ELR) motif amino terminal to the CXC
residues further subclassifies the CXC chemokines into ELR-CXC or non-ELR
families. The ELR-CXC family of chemokines was initially thought to function
exclusively on neutrophils (Hebert, Vitangcol, and Baker, 1991) but also induce
angiogenesis via endothelial cells (Addison et al., 2000; Coughlan et al., 2000;
Strieter et al., 1995b). The vCXCL-1 protein is a member of the ELR-CXC
chemokine family (Sparer et al., 2004). Indeed, vCXCL-1Tol (the subscript
indicates the strain from which the protein is derived, e.g. Toledo) was shown to
bind exclusively to CXCR2 and to induce calcium flux and chemotaxis of
neutrophils (Penfold et al., 1999). Penfold et al. speculated that the induction of
neutrophils could be used as a means for viral dissemination, thus increasing
virulence.

In

fact,

HCMV

can

be
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isolated

from

neutrophils

in

immunocompromised patients (Martin et al., 1984; Saltzman, Quirk, and Jordan,
1988; van der Bij et al., 1988a) and neutrophilic infiltrates are found in AIDS
patients who have CMV related retinitis (Holland et al., 1983; Pepose et al.,
1985). The UL146 gene, which produces the vCXCL-1 protein, is absent in an
attenuated lab strain, AD169, and based on these findings, the vCXCL-1 protein
has been hypothesized to be a potential virulence factor (Cha et al., 1996).
Testing this hypothesis in vivo is limited by the species specificity of
cytomegaloviruses. In this study we wished to further evaluate the effects of
vCXCL-1Tol on neutrophil function in vitro and to compare those findings with host
chemokines and a related chemokine from chimpanzee CMV (CCMV).
vCXCL-1CCMV was chosen for comparison to vCXCL-1Tol to evaluate
whether the conservative substitution in vCXCL-1CCMV’s ELR motif and variability
in the N-loop region, both of which are considered important to receptor binding
and triggering for host chemokines (Clark-Lewis et al., 1993; Clark-Lewis et al.,
1994; Lowman et al., 1996) affect protein function. In our work presented here,
we compare differences in receptor binding affinity, cellular activation, signal
transduction, chemotaxis, upregulation of adhesion molecules, and antiapoptotic
functions, between vCXCL-1Tol, vCXCL-1CCMV, and host chemokines.
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Materials and Methods
Cells and Viral DNA
SF9 insect cells were cultured in SF900 II media (Gibco) supplemented
with 5% FBS, 2 mM L-glutamine, and 1% gentamicin (Biowhittaker). HiFive
insect cells (Cellgro) were cultured in Insect Express media (Biowhittaker).
Chimpanzee cytomegalovirus DNA was generously provided by Dr. Gary
Hayward (Johns Hopkins School of Medicine).
Sequence Analysis
Amino acid sequence alignments of vCXCL-1Tol and vCXCL-1CCMV were
performed using the clustalW algorithm of MegAlign sequence analysis software
(DNASTAR). SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP/) was used to
predict the signal sequence cleavage sites of vCXCL-1CCMV and vCXCL-1Tol.
Protein Purification and Analysis
The vCXCL-1 gene, UL146, was PCR amplified from either HCMV or
CCMV viral DNA and cloned into the baculovirus transfer plasmid 1392
(Invitrogen), which contains homologous regions for recombination into the
baculovirus genome. PCR primers were designed to include the coding
sequence for six histidines on the carboxyl terminus of the proteins for
purification and Western blotting. SF9 cells were transfected with the plasmid
construct and Sapphire linearized baculovirus DNA (Orbigen). Recombinant
baculovirus containing the UL146 gene from either HCMV or CCMV was titered
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and used to infect HiFive cells for optimum protein expression. Cells were
harvested after 48 hours of incubation and protein was isolated from the
supernatants using Ni-NTA agarose beads (Qiagen) and resuspended in PBS.
Protein concentration was quantified using the Bradford assay (Biorad) according
to the manufacturer’s instructions.
N-terminal sequencing was used to verify cleavage of the signal peptide.
100 pmol of vCXCL-1CCMV and vCXCL-1Tol was run on a 15% SDS-PAGE gel
and then blotted onto PVDF membrane. The protein bands were excised from
the membrane and analyzed by the Stanford PAN facility using de novo Nterminal sequencing.
Receptor Binding Analysis
The ability of vCXCL-1CCMV and vCXCL-1Tol to compete for binding to
CXCR2 was evaluated as previously described (Penfold et al., 1999). Briefly,
HEK293 cell transfectants over-expressing CXCR2 were incubated with
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labeled CXCL1 and increasing concentrations of unlabeled chemokines. Cells
were collected on glass filters, washed, and bound radioactivity was measured
by liquid scintillation counting.
Activation of Signal Transduction Pathways
Differentiated HL-60 cells stably expressing CXCR2 were stimulated with
different chemokines at 100nM for 1 min at room temperature and lysed in 2x
RIPA buffer containing protease and phosphatase inhibitors (Walker et al., 2005).
20 ug of total protein was then run on a 10% SDS PAGE and immunoblotted with
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antibodies against phosphorylated Akt (Thr 308) (Cell Signal Technology), Akt,
phosphorylated ERK, and ERK (Santa Cruz Biotechnology).
Neutrophil Isolation
Peripheral blood neutrophils (PBN) were isolated from EDTA-treated
blood from healthy human volunteers using dextran sedimentation and density
gradient centrifugation as previously described (Markert, Andrews, and Babior,
1984). Erythrocytes were removed by hypotonic lysis. Neutrophils were
resuspended in buffer or media as stated for the individual assays. Viable
neutrophils were quantified by trypan blue exclusion. The use of human subjects
has been approved by the University of Tennessee institutional review board
(IRB# 6476B).
Intracellular Calcium Mobilization Assays
Release of calcium from intracellular stores was determined in freshly
isolated PBN resuspended in PBS. Cells were loaded with 3g/ml Indo-1-AM
(Molecular Probes) for 60 minutes at 37°C. Cells were washed one time with
PBS and diluted to 3-5 x 106 cells/ml in Hanks’ balanced salt solution (HBSS)
containing Ca2+ and Mg2+ and 1% FBS. Chemokines were added at varying
concentrations to 2 ml of cells. All host chemokines were purchased from
Peprotech (Rocky Hill, NJ) and endotoxin levels were less than 0.1 ng per µg
(1EU/µg).

Calcium release was measured using a Photon Technology

International Spectrophotometer (New Jersey) at an excitation of 350 nm.
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Relative intracellular calcium levels were expressed as the ratio of emissions at
490 nm to the emissions at 400 nm (Sparer et al., 2004).
PBN Migration Assays
Migration assays were performed on human PBN resuspended in HBSS
with 0.1% BSA and 10mM HEPES. Assays were performed in triplicate in 96-well
chemotaxis plates. 20 l of chemokines were loaded at varying concentrations
into the lower well of the modified Boyden chamber (Neuroprobe) and fitted with
a 5M filter. 1x106 PBN in 30 l were added to the upper well. The cells were
incubated for 3 hr at 37°C. Migration of PBN was measured by direct count of
cells that had migrated through the filter into the lower chamber. The chemotactic
index was calculated as the number of cells that migrated in the presence of
chemokine divided by the number of cells that migrated due to buffer only.
Apoptosis Assays
PBN were resuspended in RPMI-1640 (Biowhittaker) with 1% FBS and
added to a 96-well plate at 1x106 cells/well. Chemokines were added to the wells
at a final concentration of 100 nM. Plates were incubated at 37°C, 5% CO2 for 24
hrs. Cells were labeled with AnnexinV and propidium iodide (PI) using the
Annexin V Kit (Caltag) according to the manufacturer’s instructions. Cells were
analyzed by flow cytometry using FACS Calibur (Beckman-Coulter) within one
hour.
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CD11 Staining
PBN were resuspended in RPMI-1640 (Biowhittaker) with 1% FBS and
added to a 96-well plate at 1x106 cells/well. PBN were exposed to 100 nM of
chemokines for 2 hr at 37°C and 5% CO2. Cells were washed with PBS and
blocked with 1% goat serum. PBN were incubated with fluorescently conjugated
CD11a, CD11b, and CD11c antibodies (Caltag) on ice and fixed with 4%
paraformaldehyde. Cells were analyzed by flow cytometry.

Results
Comparison of amino acid sequences.
Sequence analysis indicates vCXCL-1CCMV has limited homology to
vCXCL-1Tol, CXCL1, and CXCL8 (Figure 2). Although the amino acid sequences
show relatively low homology, all share important characteristics of CXC
chemokines, including an N terminal signal peptide, spacing of the four
conserved cysteines, and an ELR like motif. The ELR-CXC motif is present in all
CXC chemokines that bind CXCR1 and CXCR2.

While the vCXCL-1 from

clinical isolates sequenced previously display conservation of this ELR-CXC
motif (Arav-Boger, Zong, and Foster, 2005; Lurain et al., 2006; Prichard et al.,
2001), it is modified in vCXCL-1CCMV with an LM conservative substitution.
Even though this is a conservative substitution, this replacement could affect
neutrophil function based on published results showing that host chemokines
with a modified ELR motif are subsequently impaired for receptor binding and
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Figure 2. Amino acid alignment of the mature forms of CXCL1, CXCL8, vCXCL1CCMV, and vCXCL-1Tol. Residues that are 100% conserved are indicated above
the alignment. The N-loop region is residues 10-20. vCXCL-1CCMV is 22%
identical and 52% similar to vCXCL-1Tol, 17% identical and 33% similar to
CXCL1, and 18% identical and 40% similar to CXCL8.
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calcium mobilization (Clark-Lewis et al., 1993; Hebert, Vitangcol, and Baker,
1991). Overall, the vCXCL-1Tol and vCXCL-1CCMV proteins are 52% similar with
only 22% identity. This observation mirrors the low identity previously observed in
the sampling of human clinical isolates, suggesting that only core, conserved
regions of the protein are required for functionality. The N-loop region is another
domain that is important for receptor engagement and function. This region lies
between the second cysteine and the 310 helix usually from amino acids 10-20
(Fernandez and Lolis, 2002). Only a conserved proline residue within the N loop
is conserved between the two proteins (Figure 2). These differences in primary
amino acid sequence may have pleiotropic effects. Alterations in these domains
may lead to differences in affinity that subsequently alter binding and/or function.
We set out to determine whether the variability within vCXCL-1CCMV results in
differences in function.
vCXCL-1 proteins can be produced and purified using the baculovirus
expression system.
In order to address functional differences between host and viral
chemokines, we generated both proteins using recombinant baculovirus. We
chose this system because baculovirus expression systems utilize the
mammalian signal peptidase cleavage site and generate eukaryotic glycosylation
patterns and folding. Following infection of HiFive cells with recombinant
baculovirus expressing the His-tagged viral chemokines, the secreted protein
was purified using Ni-NTA agarose beads. A silver stain of the isolated proteins
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indicates the high purity achieved in the isolation procedure (Figure 3A). The
apparent size of both vCXCL-1CCMV and vCXCL-1Tol at approximately 14 kDa is
larger than the predicted 10 kDa. The differences in molecular weight were due
to glycosylations (both have two predicted N-linked glycosylation sites) as
subsequent digestion with the glycosidase, PNGase F, generated proteins of the
predicted size (10 kDa) (data not shown). Mass mapping of trypsin-digested
vCXCL-1CCMV and vCXCL-1Tol proteins confirmed the identities of the isolated
proteins (data not shown). N-terminal sequencing confirmed proper cleavage of
the signal peptide (Figure 3B). Proper cleavage of the signal sequence is critical
for chemokine function (Clark-Lewis et al., 1991). In fact, alteration by the
addition or deletion of a single amino acid has been shown to abrogate the
function of some chemokines (Proudfoot et al., 1999; Proudfoot et al., 1996). Nterminal sequencing indicated the signal peptide of vCXCL-1CCMV was cleaved at
the threonine residue directly preceding the EMR-CXC motif as predicted by the
SignalP program (Figure 3B). Of the two possible cleavage sites predicted for
vCXCL-1Tol cleavage occurred at the threonine residue (T23) corresponding to
that of vCXCL-1CCMV. Our data show that the T23 site is the preferential cleavage
site. A synthetic vCXCL-1Tol based on the other signal sequence cleavage site
(Y18) was previously shown to be 100-fold less active than that cleaved at the
threonine residue corresponding to the N terminus in our preparations (Penfold et
al., 1999). This is the first confirmation that this cleavage site is used for naturally
processed vCXCL-1Tol indicating that the active form of the protein is
preferentially synthesized.
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Figure 3. vCXCL-1 protein production. A) vCXCL-1CCMV and vCXCL-1Tol
production in baculovirus. 1 mg of 6His-tagged protein eluted from nickel beads
was run on a 15% SDS PAGE gel and silver-stained. B) N-terminal sequencing
confirmed the predicted cleavage of the signal peptide of vCXCL-1CCMV and
vCXCL-1Tol.
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vCXCL-1CCMV induces intracellular calcium release in PBN.
With the differences noted in primary amino acid sequence, we assessed
whether these differences correlate with differential functions. The release of
intracellular calcium is often used as an indicator of chemokine induction of
cellular activation (Murphy, 2003). We examined the ability of vCXCL-1CCMV to
induce intracellular calcium mobilization in freshly isolated PBN. The dose
response analyses of vCXCL-1CCMV and vCXCL-1Tol showed similar activation
potential (Figure 4), demonstrating that the amino acid differences did not alter
triggering of intracellular calcium release.
Previous work demonstrated the ability of vCXCL-1Tol to desensitize PBN
activation following exposure to a number of human chemokines, including
CXCL1 (Penfold et al., 1999). Receptor desensitization is determined by the
receptor affinity for the chemokine, phosphorylation of the carboxyl terminus, and
subsequent  arrestin binding. We confirmed the ability of vCXCL-1Tol to
desensitize PBNs to CXCL1 activation. However, CXCL1 is not able to
completely desensitize to vCXCL-1Tol (Figure 5A).
The desensitization profile of vCXCL-1CCMV (Figure 5B) was compared to
that of vCXCL-1Tol. Unlike vCXCL-1Tol, vCXCL-1CCMV is unable to completely
desensitize PBN to activation via CXCL1.

In addition CXCL1 is able to

completely desensitize to vCXCL-1CCMV added to PBN following CXCL1. Because
CXCL1 binds only to CXCR2, its ability to inhibit vCXCL-1CCMV calcium
mobilization suggests that vCXCL-1CCMV, like vCXCL-1Tol, binds via CXCR2.
Treatment of cells with the CXCR2 inhibitor, SB 225002, prior to exposure to
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Figure 4. vCXCL-1CCMV has a similar activation threshold as vCXCL-1Tol and can
be desensitized by CXCL1. Changes in fluorescence were measured over time
after exposure of human PBN to different concentrations of vCXCL-1CCMV or
vCXCL-1Tol. Arrows indicate the time of addition of the chemokine.
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Figure 5. Desensitization profile of vCXCL-1Tol /CXCL1 (A.) and (B.) vCXCL1CCMV /CXCL1. 100nM of CXCL1, vCXCL-1CCMV, or CCL5 were added at the
times indicated by the arrow.

A second addition of 100nM of the indicated

chemokine was added at 90 seconds. Changes in fluorescence were measured
over time. Data is representative of five experiments.
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vCXCL-1CCMV resulted in minimal calcium mobilization further indicating that
vCXCL-1CCMV functions via CXCR2 (data not shown). The incomplete
desensitization to CXCL1 is likely due to a lower affinity of human CXCR2
(hCXCR2) for vCXCL-1CCMV. Alternatively, a reduced ability of vCXCL-1CCMV to
initiate phosphorylation of CXCR2 to the same degree as vCXCL-1Tol could result
in lower levels of receptor desensitization (Richardson et al., 2003). These
results indicate that vCXCL-1Tol engages hCXCR2 differently than vCXCL-1CCMV
such that different desensitization patterns are triggered.
vCXCL-1CCMV has reduced affinity for CXCR2 compared to vCXCL-1Tol or
CXCL1.
The ability of CXCL1 to desensitize to vCXCL-1CCMV in the calcium
mobilization assays suggests this viral chemokine binds to CXCR2. However, the
lack of complete desensitization when vCXCL-1CCMV was used to desensitize
against CXCL1 could reflect differences in receptor binding affinity for the viral
chemokine. To test this possibility, competition-binding assays were used to
evaluate the ability of vCXCL-1CCMV to compete for binding to CXCR2.
1CCMV was able to compete with
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vCXCL-

I CXCL1 for binding to hCXCR2, albeit at a

higher 50% inhibitory concentration (IC50) than that required for CXCL1 or
vCXCL-1Tol (Figure 6). We conclude that vCXCL-1CCMV binds to hCXCR2 but with
a lower affinity than vCXCL-1Tol (vCXCL-1Tol IC50 = 0.9 nM versus vCXCL-1CCMV
IC50=65 nM) and this may explain the differences in desensitization patterns seen
in Figure 5B (i.e. CXCL1 can prevent subsequent calcium flux via vCXCL-1CCMV
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Figure 6. vCXCL-1CCMV binds with less affinity than vCXCL-1Tol to CXCR2. 293
cells stably expressing only CXCR2 were incubated with a constant amount of
125I-CXCL1 and increasing amounts of unlabeled chemokines. Calculated IC50
values are indicated in molar concentrations in parentheses.
representative of two experiments.
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Data is

while vCXCL-1CCMV cannot desensitize to exposure to CXCL1). Affinity may not
be the sole explanation for the differences between vCXCL-1Tol desensitization
patterns with CXCL1 (Fig. 3B), yet no differences in the calcium flux activation
potentials of vCXCL-1CCMV and vCXCL-1Tol were seen (Fig. 4).

The viral

chemokines could be engaging the receptors differently such that  arrestins are
not activated as efficiently. This would explain the differences in desensitization
patterns while not affecting the activation potentials.
vCXCL-1CCMV induces migration of human neutrophils.
An important function of chemokines is their ability to induce chemotaxis
of a variety of cells. ELR-CXC chemokines and vCXCL-1Tol trigger migration of
neutrophils (Penfold et al., 1999). We tested the ability of vCXCL-1CCMV to induce
migration of human PBN using a modified Boyden chamber. vCXCL-1CCMV
induces migration of neutrophils with equal potency as the host chemokine,
CXCL1 (Figure 7).

Therefore, vCXCL-1CCMV chemoattracts PBNs efficiently in

spite of differences with vCXCL-1Tol in affinity for hCXCR2 and primary amino
acid sequences.
vCXCL-1CCMV activates ERK and Akt signaling pathways.
The differences in affinity between the chemokines may affect functional
activation (Clark-Lewis et al., 1994; Clark-Lewis et al., 1991; Geiser et al., 1993;
Wu et al., 1996) as we observed with the receptor desensitization patterns
(Figure 5). Upon CXCR2 binding, G protein signal transduction cascades are
activated (De Lean, Stadel, and Lefkowitz, 1980). Two of the central signal
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Figure 7. vCXCL-1CCMV induces migration of neutrophils. Migration assays were
performed by loading human PBN onto the upper chamber of a 96-well plated
fitted with a 5mm filter with increasing amounts of chemokine loaded in the lower
chamber. Results are reported as a chemotactic index of the number of cells
migrated divided by the random migration +/- s.d. Data is representative from
three experiments.
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transduction cascades activated upon CXCL1 binding to CXCR2 are the
extracellular signal-related protein kinase (ERK), a member of the mitogenactivated protein (MAP) kinase family (Shyamala and Khoja, 1998) and protein
kinase B/Akt pathway, which is activated via the phophoinositide-3 kinase
signaling cascade. The activation of the ERK and Akt signaling pathways are
triggered following exposure to chemokines and -arrestin activation (Lefkowitz
and Shenoy, 2005). In order to assess whether the differences in binding to
CXCR2 induce different signaling cascades, we analyzed the activation profile of
differentiated HL-60 cells stably expressing CXCR2 following exposure to
vCXCL-1CCMV. HL60s were used due to the difficulty of isolating fresh PBNs
without inadvertent signal transduction activation and because of host-to-host
variation. Exposure of differentiated HL-60 cells to vCXCL-1CCMV and vCXCL-1Tol
resulted in phosphorylation of both ERK and Akt to similar levels as the CXCL8
and CXCL1 controls (Figure 8).

At least for these two important signaling

pathways, the affinity for hCXCR2 does not markedly impact activation.
vCXCL-1CCMV upregulates CD11b and CD11c on the surface of PBN.
2 integrins, including CD11a, CD11b, and CD11c, are membrane bound
receptors present on leukocytes that are necessary for PBN adhesion to and
migration across the endothelium (Mayadas and Cullere, 2005). Because of their
potential importance in recruitment of PBN to the site of CMV infection, we tested
the ability of vCXCL-1CCMV and vCXCL-1Tol to alter surface expression of these
receptors on PBN. Exposure of human PBN to vCXCL-1CCMV and vCXCL-1Tol
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Figure 8. Both viral and host chemokines activate the ERK and Akt pathways.
Differentiated HL-60 cells stably expressing CXCR2 were stimulated with 100nM
chemokine for 1 min at room temperature and lysed instantly. Lysates were
immunoblotted

using

antibodies

against

the

phosphorylated

(p)

and

unphosphorylated ERK and Akt proteins as indicated. This is representative of
two experiments.
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resulted in no change in the levels of CD11a expressed on the cell surface
(Figure 9). However, CD11b and CD11c levels increased upon exposure to
vCXCL-1CCMV (30% and 12% above control respectively) and to similar levels as
CXCL1 (51% and 11%) (Figure 9). Interestingly, vCXCL-1Tol also increased
expression of these proteins on PBN but to somewhat higher levels (106% and
36%) compared to CXCL1 or vCXCL-1CCMV. PBN exposed to CXCL8 showed
similar levels of CD11b/c expression (106% and 46%) as those exposed to
vCXCL-1Tol.

These results imply that the two viral chemokines differentially

induce adhesion molecule upregulation:

vCXCL-1Tol is similar to CXCL8

stimulation and vCXCL-1CCMV is similar to CXCL1. These data show that amino
acid differences between these chemokines can lead to different activation
profiles on PBN that could affect their functions in vivo.
vCXCL-1CCMV decreases apoptosis of human PBN.
PBN normally undergo apoptosis in 24-48 hours (Haslett, 1992). Because
PBN play a role in the dissemination of HCMV (Gerna et al., 2000; Gerna et al.,
1992), HCMV may have evolved viral chemokines that alter PBN viability. We
assessed the capacity of vCXCL-1CCMV and vCXCL-1Tol to alter apoptosis of
PBN. We found that vCXCL-1CCMV and vCXCL-1Tol decreased apoptosis (17%
vs. 29% respectively) (Figure 10). This decrease was similar to CXCL1 (21%).
However, it was not as great as the reduction following exposure to CXCL8
(44%). Any differences in the longevity of neutrophils could affect viral survival or
dissemination in vivo, which eventually affects HCMV pathogenesis.
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Figure 9. vCXCL-1Tol and vCXCL-1CCMV differentially increase CD11b and CD11c
expression on the surface of neutrophils. Human PBN were incubated in the
presence of 100nM of different chemokines (vCXCL-1Tol, vCXCL-1CCMV, CXCL1,
or CXCL8) and labeled with fluorescently-conjugated antibodies against CD11a,
CD11b, and CD11c.

The table summarizes the flow cytometry data and is

expressed as percent change in the mean fluorescent intensity compared to nonstimulated PBN. This is a representative experiment of three experiments.
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Figure 10. vCXCL-1CCMV and vCXCL-1Tol reduce apoptosis in neutrophils. Human
PBN were incubated for 24 hrs in the presence of either viral or human
chemokines (100nM). After incubation, cells were labeled with annexin-FITC and
propidium iodide and then analyzed by flowcytometry. The percent reduction in
apoptosis relative to the non-stimulated cells is summarized in the table. This is
a representative experiment of five experiments.
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Discussion
The significant findings of this paper are that two distantly related viral
chemokines (vCXCL-1Tol and vCXCL-1CCMV) have similar functions in spite of
distinct differences in affinity for CXCR2 and amino acid composition in the N
loop and ELR motifs. These regions of host chemokines have been shown to
play a role in receptor binding and activation (Clark-Lewis et al., 1993; Fernandez
and Lolis, 2002; Hebert, Vitangcol, and Baker, 1991). Although vCXCL-1CCMV
was able to bind CXCR2, it was not able to bind with as high of an affinity as
vCXCL-1Tol or CXCL1 in competition binding studies (Figure 6). This difference
could reflect the difference in affinity of vCXCL-1CCMV for human CXCR2 versus
chimpanzee CXCR2 in these assays. However, the CXCR2 receptor in these two
species is highly conserved. Chimpanzee CXCR2 is 99% identical to human
CXCR2 based on amino acid comparisons. Only 2 amino acids out of 355 are
different. These two amino acids are located in transmembrane regions 5 and 7
(Alvarez et al., 1996). Importantly, the transmembrane regions of CXCR2 that are
known to be important for receptor structure are conserved between the human
and chimpanzee receptors (Baggiolini, Dewald, and Moser, 1997). It is possible
that binding motifs and structural differences not yet identified could result in
differential binding of vCXCL-1CCMV to hCXCR2, although this seems unlikely.
It is perhaps more likely that differences in the viral chemokines
themselves are responsible for the differences in binding affinity. This may be
due in part to the mutated ELR motif (LM) present in vCXCL-1CCMV. The ELR
motif is known to be important in receptor binding and signaling (Clark-Lewis et
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al., 1991; Schraufstatter et al., 1993). Mutagenesis of each of the ELR residues
of CXCL8 reduced the ability of CXCL8 to competitively bind to neutrophils and
CXCR2 expressing cell lines (Hebert, Vitangcol, and Baker, 1991). However,
these mutations did not completely eliminate receptor binding and other regions,
such as the N-loop region, are also important in receptor binding (Fernandez and
Lolis, 2002). vCXCL-1CCMV only shares the single amino acid, proline, with
CXCL1 in this region and the sequence diversity in this region may contribute to
the differences seen in binding affinity. Additionally, the presence of a glycine at
residue 31 has been shown to be important for receptor binding (Clark-Lewis et
al., 1994; Clark-Lewis et al., 1995; Li et al., 2002). vCXCL-1C956 from a clinical
isolate of HCMV has a substitution at the G31 residue but shows equivalent
binding to CXCR2 and an equal capacity for inducing calcium mobilization to
levels comparable to CXCL1 (unpublished data). This data demonstrates that a
substitution at this residue is not solely responsible for the lower binding affinity
of vCXCL-1CCMV to CXCR2. Finally, the carboxyl terminus plays some role in the
function of chemokines. Although not thought to be important in all cases, the
carboxyl terminal region of CXCL1 has been implicated in receptor binding (Roby
and Page, 1995). The C-terminal region of the viral chemokines is considerably
longer than that of CXCL1 and CXCL8 and may contribute to differential binding
or signaling of the receptor (Figure 2 and (Penfold et al., 1999)).
Evolution has directed the variation of HCMV genes such that viral genes
have similar functions with limited homology to host genes. As discussed above,
vCXCL-1 shows sequence variation from its cellular counterpart, CXCL1.
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Additionally, sequencing of human CMV clinical isolates has revealed extreme
sequence variability between strains, with only limited regions of conservation
and identities below 30% (Arav-Boger et al., 2006b; Prichard et al., 2001).
Similarly UL144, a viral tumor necrosis factor (TNF)-alpha-like receptor gene,
displays high variance in its sequence between clinical strains and correlates
with severity of congenital disease (Arav-Boger et al., 2006a; Arav-Boger and
Pass, 2002). Both human and rhesus CMVs encode interleukin 10 homologs,
which retain functionality despite a sequence identity of less than 30% to their
cellular counterparts (Kotenko et al., 2000; Spencer et al., 2002). Such variability
among secreted and surface-displayed proteins may be driven by selective
immune pressures, although why certain genes appear more susceptible to
these pressures than others is unknown.
An important question is whether the reduced binding affinity by vCXCL1CCMV results in differences in the functional capacity of this protein. Relative
differences in activity between CXCL8 and vCXCL-1CCMV can be difficult to
assess based on the ability of CXCL8 to bind and signal via both CXCR1 and
CXCR2, whereas vCXCL-1CCMV, based on our data, only activates CXCR2.
Therefore, we also compared the biological activity of vCXCL-1CCMV to the
CXCR2-specific chemokine, CXCL1. As we have shown, vCXCL-1CCMV induces
activity in most biological assays comparable to that of CXCL1. Given the lower
binding affinity of vCXCL-1CCMV, we also tested the activation profile of vCXCL1CCMV at 1M, which is fifteen fold above the IC50, to ensure complete saturation
of all expressed receptors. However, the higher concentration of vCXCL-1CCMV
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did not result in a greater calcium flux than at 100nM, therefore it is reasonable to
assume that the receptors were saturated at the 100nM concentration used in
these experiments. This leads us to conclude that lower receptor binding affinity
does not correlate with a reduction in biological activity when compared with
CXCL1. One exception where reduced binding affinity may be important is the
ability of vCXCL-1CCMV to completely desensitize neutrophils upon subsequent
exposure to CXCL1. In this case, the ability of CXCL1 to compete more
effectively (i.e. higher binding affinity) for binding to CXCR2 allows it to displace
vCXCL-1CCMV and induce a second wave of calcium mobilization. Interestingly,
vCXCL-1CCMV was unable to desensitize PBN to CXCL1 even when used at a 10fold higher concentration compared to CXCL1 (data not shown) suggesting the
lack of complete desensitization may be due in part to differential activation and
phosphorylation of CXCR2. Phosphorylation of G protein-coupled receptors
prevents reassociation of the G protein and the receptor, resulting in a receptor
that is desensitized to further stimulation by ligand (Neel et al., 2005).
vCXCL-1Tol was previously found to function via CXCR2, inducing calcium
mobilization and chemotaxis of PBN with a potency comparable to CXCL8
(Penfold et al., 1999). We have verified similar findings for the CCMV viral
chemokine, vCXCL-1CCMV. vCXCL-1CCMV showed a similar profile of calcium
mobilization as vCXCL-1Tol at the concentrations tested. Additionally, vCXCL1CCMV was able to induce migration of neutrophils as effectively as CXCL1. The
ability of vCXCL-1CCMV to induce PBN chemotaxis could enable the virus to
modulate the immune response to benefit viral survival or dissemination. An
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example of a viral chemokine that functions in viral dissemination is the MCK2
chemokine from murine cytomegalovirus (MCMV) (Fleming et al., 1999;
Saederup et al., 2001; Saederup et al., 1999). Infection of mice with MCMV
lacking the MCK chemokine gene resulted in decreased inflammation at the site
of infection and dissemination of the virus. This evidence illustrates the ability of
viral chemokines to alter the immune response in vivo (Saederup et al., 2001).
Although these chemokines are from two different chemokine families (CXC for
vCXCL-1CCMV and CC for MCK2), they could be functional homologues. This is a
common theme for CMVs. Other immune modulatory proteins such as the class
I down regulating proteins from the M152 gene in MCMV (Ziegler et al., 1997)
and the US2, US3, and US11 genes in HCMV (Gewurz et al., 2001a; Landolfo et
al., 2003; Rehm et al., 2002) lack sequence homology yet both viruses achieve
the same end result of down-regulation of antigen presentation.
Chemotaxis of circulating neutrophils is dependent on adhesion to and
extravasation across the endothelium. This process can be mediated by the
interaction of 2 integrins present on the surface of PBN with their ligands on
endothelial cells. The 2 integrin family includes CD11a, CD11b, CD11c, and
CD11d. Previous studies demonstrated the ability of the chemokines, CXCL8
and CXCL1, to upregulate CD11b expression (Detmers et al., 1990). Here we
demonstrate that both vCXCL-1CCMV and vCXCL-1Tol increase CD11b and CD11c
expression on the cell surface. Furthermore, CXCL8 upregulation of CD11b on
PBN involves the ERK signaling pathway (Takami, Terry, and Petruzzelli, 2002),
which was shown to be upregulated by both viral chemokines (Figure 8).
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Therefore, these viral chemokines could enhance the ability of PBN to adhere to
and cross the endothelium allowing migration of neutrophils through the tissue to
the site of infection.
Regulation of apoptosis of neutrophils could also provide an advantage to
HCMV by allowing PBN to survive and disseminate HCMV.

In fact HCMV

produces several proteins that alter apoptosis in infected cells (McCormick et al.,
2005; Smith and Mocarski, 2005). Our results show that vCXCL-1CCMV, vCXCL1Tol, and CXCL1 reduce apoptosis to similar levels. CXCL8 shows the highest
reduction in apoptosis however this chemokine has also been shown to alter
apoptosis primarily via CXCR1 (Glynn, Henney, and Hall, 2002) through
activation of the ERK and Akt pathways in neutrophils (Akgul, Moulding, and
Edwards, 2001; Khreiss et al., 2004). The similarity in vCXCL-1CCMV and vCXCL1Tol activation of the ERK and Akt pathways suggests that other pathways must
also be involved. Prolonging PBN survival would be advantageous for HCMV.
The longer the neutrophil is viable the greater the chance it will be used for
dissemination (Grundy et al., 1998).
In conclusion, we have shown that the CCMV viral chemokine has similar
biological activities to vCXCL-1Tol and CXCL1 except for integrin upregulation
and inhibition of apoptosis. This is in spite of differences in binding affinities and
amino acid variability in the N-loop region and ELR motif. A similar example is
found in human herpesvirus 8 (HHV8) viral chemokines vMIP I and vMIP II
(Boshoff et al., 1997; Kledal et al., 1997).

Both chemokines have limited

homology (38% and 41% respectively) to host chemokines CCL2 (MIP1) and
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CCL5 (RANTES) (Fernandez et al., 2000).

These chemokines have similar

functions to host chemokines yet can act as antagonists and bind to additional
host chemokine receptors. Although we have not found antagonistic functions
for vCXCL-1s, vMIP II is yet another example of a herpesvirus evolving a
chemokine with unique functions.
We can infer from our data that very simple structural motifs guide
receptor binding and activation rather than specific amino acid-to-amino acid
interactions. The eotaxin family of host chemokines provides a similar example.
These chemokines also have considerable variability yet slight differences in
binding and activation (Forssmann et al., 1997; Kitaura et al., 1999; Shinkai et
al., 1999; White et al., 1997). All eotaxins bind and/or activate the same eotaxin
receptor, CCR3, in spite of very little amino acid identity (Duchesnes et al.,
2006). There is some variability in the responses to the different eotaxins leading
to speculation that these proteins may exist to “fine-tune” their interaction with
their receptor to produce different biological outcomes. We propose that the
variability in the viral chemokines helps to fine tune the neutrophil response,
which allows for more efficient HCMV dissemination.

This explains the high

degree of variability that occurs naturally in HCMV isolates (He et al., 2006) and
between their homologous host chemokines.

The vCXCL-1s from different

strains of HCMVs could allow for increased dissemination via find tuned
alterations of apoptosis and integrin expression that provides a survival
advantage in the specific hosts.
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Chapter 4
In Vivo Analysis of a Recombinant MCMV Expressing the
Chimpanzee Cytomegalovirus Chemokine, vCXCL-1CCMV
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Abstract
Many CMVs encode viral homologs of chemokines that may be involved in
viral dissemination. The virulent HCMV lab strain, Toledo, produces a functional
CXC chemokine, vCXCL-1Tol. The species specificity of the CMVs limits analysis
of this protein’s role in vivo. The closely related chimpanzee cytomegalovirus
produces the related homolog, vCXCL-1CCMV, with similar in vitro function. The in
vivo function of vCXCL-1CCMV may correlate with its HCMV homolog and CCMV
may be a valuable non-human primate system for these studies. MCMV is a wellestablished model of CMV pathogenesis and dissemination and was chosen to
initially characteize vCXCL-1CCMV. We generated the recombinant MCMV,
RMvCXCL-1CCMV, to assess the role of vCXCL-1CCMV in virus dissemination in
vivo. RMvCXCL-1CCMV had similar 1 dissemination as the parental strain,
RM4511, but was not detected in the salivary gland following 2 dissemination.
This was not due to clearance of RMvCXCL-1CCMV by the adaptive immune
response or neutrophils of innate immunity. Our data suggest RMvCXCL-1CCMV
likely has a defect in dissemination to the salivary gland possibly due to
overexpression of vCXCL-1CCMV.

Introduction
Human cytomegalovirus (HCMV) is a -herpesvirus that infects between
50% and 90% of the population resulting in largely asymptomatic infections
(Pass,

1985).

However,

HCMV

can

cause

serious

complications

in

immunocompromised individuals and newborns (Pass, 2001). Primary or
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reactivated HCMV is a frequent cause of retinitis in AIDS patients (Cheung and
Teich, 1999) and increases the incidence of organ rejection and graft versus host
disease in transplant recipients (Ljungman, 1996; McCarthy et al., 1992). Central
nervous system damage due to congenital HCMV infection affects between 5000
and 8000 newborns in the U.S. each year (Adler, 2005). As a result, HCMV is the
leading cause of infectious hearing loss and non-hereditary mental retardation
(Pass, 2001). Due to the long-term morbidity associated with CMV congenital
infections, the Institute of Medicine lists the development of a CMV vaccine as a
top priority (Arvin et al., 2004).
Understanding HCMV pathogenesis is important for the development of
an effective vaccine or novel therapeutics. However, CMV pathogenesis is
complex. CMVs encode numerous proteins that modulate or suppress the host
immune system. CMV can inhibit apoptosis of infected cells, impair antigen
processing, and alter the inflammatory response including the chemokine
network (Mocarski, 2002). Chemokines are small, chemotactic cytokines that are
important for leukocyte trafficking and activation. Chemokines are divided into
four groups (CC, CXC, CX3C, C) based on the spacing of their amino terminal
cysteines although most chemokines are members of either the CC or CXC
class. These chemokines attract and activate a variety of immune cells
responsible for viral clearance and contribute to CMV pathogenesis (Benedict et
al., 2006; Cavanaugh et al., 2003).
Not only does HMCV infection alter the expression of host chemokines
(Chan et al., 2008) but many CMVs also encode viral homologs of chemokines
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and their receptors (van Cleef et al., 2006). The Toledo strain of HCMV, a
virulent lab strain (Quinnan et al., 1984), produces a functional CXC chemokine,
vCXCL-1Tol. vCXCL-1Tol was found to bind the chemokine receptor CXCR2
inducing chemotaxis and calcium flux in neutrophils (Penfold et al., 1999).
Chimpanzee cytomegalovirus, a close relative of HCMV, encodes a homolog of
vCXCL-1Tol. Recently, we have shown that vCXCL-1CCMV also triggers calcium
release and chemotaxis of neutrophils.

Both HCMV and CCMV vCXCL-1

upregulate adhesion molecule expression on neutrophils and downregulate
neutrophil apoptosis, albeit with different potencies (Miller-Kittrell et al., 2007).
These findings provide circumstantial evidence for the role of vCXCL-1 in the
activation and recruitment of neutrophils for CMV dissemination. Neutrophils
have been shown to be important in HCMV dissemination in vivo. HCMV can be
recovered from neutrophils of immunocompromised patients (Saltzman, Quirk,
and Jordan, 1988; van der Bij et al., 1988b) and neutrophilic infiltrates are
present in CMV associated retinitis of AIDS patients (Holland et al., 1983;
Pepose et al., 1985). Strict species specificity of the CMVs limits the direct
evaluation of vCXCL-1 in HCMV dissemination. The function of vCXCL-1CCMV
may correlate with its HCMV homolog, although in vivo characterization of this
protein is complicated by the current lack of a chimpanzee model of CMV
infection.
MCMV is a well-established animal model of CMV infection and has
similar cell tropism and disease manifestations as HCMV (Hudson, 1979). MCMV
expresses a chemokine homolog, MCK2, which has been shown to increase the
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inflammatory response in mice and enhance dissemination of MCMV to the
salivary gland (Fleming et al., 1999; Saederup et al., 2001). Therefore, MCMV
was chosen to initially characterize vCXCL-1CCMV in vivo. Because CCMV does
not infect mice, we generated a recombinant MCMV expressing vCXCL-1CCMV in
order to assess the role of the CCMV viral chemokine in virus dissemination in
vivo.

Materials and Methods
Cells and Viruses
Murine NIH3T3 and M210B4 cells (ATCC) were propagated in DMEM
supplemented with 10% Fetalclone III (Hyclone), 1% penicillin/streptomycin, 1X
NEAA, 1% sodium pyruvate (100mM), and 0.5 % Hepes (1M). The parental
MCMV strain used in this study was MCMV RM4511 which has a 1.7 kb
puromycin-green fluorescent protein (GFP) cassette inserted into the IE2 region
and a double point mutation in the m131 gene resulting in a nonfunctional MCK2
protein (Figure 11) (Saederup et al., 2001).
Mice
3-4 week old Balb/c and SCID/NCr mice were purchased from Jackson
Laboratory (Bar Harbor, ME) or Taconic Labs, respectively. hCXCR2 transgenic
Balb/c mice express hCXCR2 under the control of the neutrophil-specific, human
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K181 (wt)
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RMmCXCL1/ (gfp -) (mck -)
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gpt

HCMV IE Chemokine

Figure 11. Schematic Representation of Wild Type (WT) MCMV, Parental MCMV
(RM4511), RMmCXCL1, and RMvCXCL1CCMV. K181, a wild type strain of MCMV,
contains the endogenous murine viral chemokine gene, mck. The RM4511
recombinant MCMV contains a double point mutation resulting in a missense
mutation that converts amino acids CC to GR. This in effect creates an MCK2
negative strain. Additionally, a green fluorescent protein (GFP)/puromycin
expression cassette was inserted into the ie2 region. The mCXCL1 or vCXCL1CCMV expression cassette containing a gpt selectable marker was inserted into
the IE2 region eliminating the puromycin-GFP to generate RMmCXCL1 and
RMvCXCL1CCMV, respectively.
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myeloid related protein-8 promoter (Sparer et al., 2004). All mice were housed
under specific pathogen free conditions.
Plasmid Constructs
An EcoRI/PstI digested fragment containing the coding region for vCXCL1CCMV or mCXCL1 (KC) was cloned into the EcoRI/PstI digested plasmid
pcDNA3.1/Zeo

immediately

downstream

of

the

human

cytomegalovirus

immediate early promoter (HCMV IE). The 1.2kb HCMV IE-chemokine fragment
was PCR amplified to add flanking restriction sites (underlined) and a C-terminal
6-His

tag

using

the

primers:

MluI

HCMV

IE

(5’-

CGACGCGTCGATGTACGGGCCAGATATACGCCTTGACATTGATTAT-3’) and
SalI 6 His (5’ACGCGTCGACTGGTGGTGGTGGTGGTGACCTCCTCC-3’). The
PCR fragment was cloned into the pCRII TA vector (Invitrogen) for sequence
verification. The HCMV IE-chemokine cassette was digested with MluI and SalI
and cloned into the plasmid L120.1 as illustrated in Figure 12. L120.1 has 5’ and
3’ sequences from MCMV IE2 for homologous recombination and a gpt
expression cassette used for selection of recombinant viruses (C. Meiering,
unpublished data).
Generation of Recombinant Virus
NIH3T3 cells (60% confluent) were transfected with Drd-linearized
L120.1+vCXCL1-1 C C M V or L120.1+mCXCL1 using Lipofectamine 2000
(Invitrogen). Three hours post-transfection, the cells were infected with MCMV
RM4511 at an MOI=3. Transfectants were harvested and passaged twice under
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DrdI

5'MCMV

pA-gpt-TK

DrdI

L120.1+(HCMV
IE-vCXCL-1
CCMV /mCXCL1)
L120.1+(HCMV
IE-vCXCL-1
CCMV

MluI

HCMV ie promoter
DrdI

vCXCL-1/mCXCL1
3'MCMV
EMVC-IRES
dsREDnuc+pA
SalI

Figure

12.

L120.1

plasmid

used

for

generating

RMvCXCL1CCMV

and

RMmCXCL1. This plasmid contains the HCMV IE promoter driving the
expression of vCXCL-1CCMV or mCXCL1, a gpt marker under the control of the
HSV TK promoter for selection of recombinant viruses and MCMV ie2
homologous regions (5’MCMV and 3’MCMV) for recombination into RM4511.
The plasmid was linearized with the restriction enzyme, DrdI, prior to
transfection.
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selection using growth media supplemented with mycophenolic acid (12.5 g/ml)
and xanthine (100 g/ml) (Vieira et al., 1994). Recombinant virus was identified
by the loss of gfp fluorescence and subjected to three rounds of plaque
purification using an overlay of 0.5% agar in growth media. Virus stocks were
generated by infecting NIH3T3 cells in T150 flasks at an MOI=0.01. Viral DNA
was isolated by phenol-chloroform extraction and used for diagnostic PCR to
verify proper insertion of the chemokine cassette and loss of the puromycin-gfp
insert.

The

primers

used

were:

CATTGACGTCAATGGTGGGAAAGTACATGGCG-3’),
CCCGACGCGCGTGAGGAAGAGTTCTTGCAG-3’),

RM4511
RM4511
and

HCMV

F

(5’-

gfp

R

(5’-

ie

R

(5’-

GAACTCCATATATGGGCTATGAACTAATGACC).
In Vitro Growth Assay
M210B4 cells (4x105cells/well) were plated in triplicate in a 6-well dish
and infected with RM4511, RMvCXCL-1CCMV, or RMmCXCL1 for either a multistep (MOI=0.5) or single-step (MOI=5) growth analysis. Supernatants were
collected at stated times post infection, centrifuged (400x g) to remove
contaminating cells and sonicated prior to titering. Virus titers were determined
by standard plaque assay on M210B4s (Lutarewych et al., 1997).
In Vitro Protein Expression
Aliquots from the single-step growth assay were removed and used to
verify chemokine expression. vCXCL-1CCMV and mCXCL1 were isolated from 100
g of total protein by incubation with Ni-NTA agarose beads. The eluted protein
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samples were subjected to Western blot analysis using the primary anti-6-His
antibody (Qiagen) diluted 1:200 and secondary anti-mouse HRP antibody diluted
1:2000 .
In Vivo Growth of Parental and Recombinant Viruses
106 PFUs of parental or recombinant viruses were inoculated in the
footpad of hCXCR2 transgenic mice. At different times post infection, mice were
sacrificed and their footpads, spleens, liver, lungs, popliteal lymph node, and
salivary glands were removed. Organs were individually weighed, sonicated in
growth medium, and centrifuged at 400 X g to pellet debris. Supernatants were
stored at -80C until titered (Fleming et al., 1999).
Depletion of Cellular Subsets
In vivo depletion of cellular subsets was performed by intraperitoneal (i.p.)
inoculation of depleting antibody one day prior to MCMV infection and then every
three days until harvest. Neutrophils were depleted using 1A8 (anti-Ly6C)
antibody (1mg/ inoculation) (BioXcell, West Lebanon, NH) (Daley et al., 2008).
Flow cytometry was used to confirm depletion of GR-1hi, Mac-1hi (Pharmingen)
neutrophils.
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Results
Generation of Recombinant Viruses.
The strict species specificity of the CMVs precludes the use of CCMV in
the mouse model. Therefore, a recombinant MCMV expressing vCXCL-1CCMV
was generated to study the role of this protein in virus dissemination. A
recombinant virus expressing the murine CXC chemokine, mCXCL1 (KC), was
generated as a control to evaluate specific effects on dissemination due to the
virally encoded chemokine. mCXCL1 was chosen as it is murine equivalent of
IL8, which is the closest homologue to vCXCL-1. MCMV RM4511 was used as
the parental strain for construction of these viruses because it lacks expression
of a functional MCMV viral chemokine, MCK2. This will allow for the in vivo
analysis of vCXCL-1CCMV and mCXCL1 in the absence of any contribution by the
MCMV encoded chemokine.
The recombinant plasmid, L120.1, was constructed to contain either the
vCXCL-1CCMV or mCXCL1 coding sequence under the control of the HCMV IE
promoter (Figure 12). This promoter has been used to drive expression of other
genes inserted in the MCMV genome (Manning et al., 1992) and was chosen to
ensure adequate chemokine expression. Insertion of the chemokine cassette into
the ie2 region displaced the puromycin-GFP segment present in RM4511 (Figure
11). Loss of GFP expression allowed visual selection of recombinant viruses.
The ie2 gene was previously shown to be dispensable for MCMV replication in
vitro and in mice (Manning and Mocarski, 1988).
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Following transfection of NIH3T3 cells with Drd-linearized L120.1+vCXCL1CCMV or mCXCL1 and subsequent infection with RM4511; recombinant viruses
were passaged twice in medium containing mycophenolic acid and xanthine to
select for recombinant virus expressing gpt. Recombinant virus was identified by
the loss of GFP expression and plaque purified three times.
PCR was used to discriminate between RM4511 and the recombinants
(Figure 13). Chemokine specific primers (forward) and a universal 6 His primer
(reverse) were used to confirm the presence of the chemokine insert. No product
was detected when the parental virus was used as a template (Fig. 13A). Two
different primer sets were designed to verify correct insertion of the promoterchemokine cassette and loss of the puromycin-gfp segment. The forward primer
was located upstream of the recombination site in the MCMV genome and was
used in both diagnostic PCRs. The reverse primer was specific for the displaced
(GFP/puromycin)(Figure 13B) or the inserted sequences (HCMV IE promoter)
(Figure 13C). Each PCR generated the expected size fragment and confirms
that the recombination occurred in the correct location with the correct
orientation.
In Vitro Growth Kinetics and Chemokine Expression of RMvCXCL-1CCMV
and RMmCXCL1.
The growth kinetics of RMvCXCL-1CCMV and RMmCXCL1 were evaluated to
determine whether insertion of the vCXCL-1CCMV or mCXCL1 cassette affected

78

Figure 13. PCR verification of RMmCXCL1 and RMvCXCL1CCMV. Three PCR
reactions were performed using viral DNA as template. A) Amplification of either
the mCXCL1 or vCXCL-1CCMV gene using HCMV IE and 6 His primers. This
generates a ~325 bp product (mCXCL1) and a ~425bp (vCXCL-1CCMV). B)
Verification of the loss of the puromycin-GFP expression cassette using a primer
flanking the 5’ MCMV IE2 homologous region and a primer within the puromycinGFP cassette (MCMV GFP). This generates a 2.3kb product. C) Verification of
the correct insertion site of the mCXCL1 or vCXCL-1CCMV expression cassette
using a primer flanking the 5’ MCMV IE2 homologous region and a primer within
the expression cassette (HCMV IE). This generates a 3kb PCR product.
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C

growth of the recombinant viruses in cell culture. We performed both single
(MOI=5) and multi (MOI=0.05) step growth curves to identify any growth defects
in replication or spread of the recombinant viruses relative to the parental strain,
RM4511. RMvCXCL-1CCMV and RMmCXCL1 replicated as well as RM4511 in
both assays (Figure 14), indicating the absence of any deleterious mutations
affecting growth in cell culture.
Before evaluating the role of RMvCXCL-1CCMV and RMmCXCL1 in vivo,
temporal expression of the chemokines in the supernatants of virally infected cell
was confirmed (Figure 15). Immunoblotting of Ni-NTA-concentrated supernatants
from each time point of the single step growth curve detected RMvCXCL-1CCMV
and RMmCXCL1. Beginning on the second day post infection and continuing for
the duration of the experiment, both chemokines were detected in the
supernatants.

This illustrates both host and viral chemokines are secreted in

detectable quantities by day 2 post infection.
Dissemination of RMvCXCL-1CCMV and RMmCXCL1 in vivo.
To evaluate the role of vCXCL-1CCMV in the dissemination of CMV in vivo,
hCXCR2 transgenic mice were inoculated with RMvCXCL-1CCMV, RMmCXCL1,
or RM4511 via the footpad to mimic natural MCMV infection. hCXCR2 transgenic
mice were used because vCXCL-1CCMV does not activate murine CXCR2 (data
not shown). Because these transgenic mice still express mCXCR2 they retain the
ability to respond to mCXCL1. This allowed the evaluation of both RMvCXCL1CCMV and RMmCXCL1 recombinants in the same mouse strain.
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Figure 14. Recombinant viruses have equivalent growth rates in vitro. NIH3T3
cells were infected in triplicate with RM4511 or RMvCXCL1CCMV at a MOI of 5
(single-step) or 0.05 (multi-step). Supernatants were harvested daily for five days
post infection. Plaque assays were performed on M210B4 cells.
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Figure 15. Recombinant viruses express either mCXCL1 and vCXCL1CCMV in
vitro. Western blot analysis was used to analyze the expression of mCXCL1 and
vCXCL1CCMV. NIH3T3 cells were infected with RM4511, RMmCXCL1, or
RMvCXCL1CCMV at a MOI of 5. Supernatants were harvested at the indicated
times post infection. Recombinant proteins were isolated using Ni-NTA agarose
beads from 100 mg of total protein. The eluted protein samples were subjected to
Western blot analysis using anti-6-His antibody to detect the 6-His tag.
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Following inoculation, virus titers were measured in several organs to
determine the impact of vCXCL-1CCMV and mCXCL1 on virus dissemination
(Figure 16). Footpad titers showed no differences, thus the viral chemokines did
not affect replication or clearance at the site of inoculation. Primary dissemination
beginning at day 2 is measured by titers in the lymph node, lung and spleen.
Once again, there were no difference between the recombinants and the parental
virus (RM4511). Surprisingly, no virus was recovered in the salivary glands at all
time points examined in mice infected with the recombinant viruses. RM4511
was present in the salivary gland but at a lower titer than the MCK2 expressing
virus, RM4503, as previously shown (Saederup et al., 2001). To ensure that
dissemination of the recombinant virus to the salivary gland was not delayed,
salivary glands were titered at 21 dpi. No virus was detected at this time point
(data not shown). The absence of the recombinant viruses in the salivary gland
could represent a defect in dissemination to this site, a lack of replication in the
salivary gland, or enhanced clearance of these viruses from the salivary gland.
The absence of RMvCXCL-1CCMV and RMmCXCL1 in the salivary gland is
not due to adaptive immune response clearance.
T cells play an important role in controlling CMV infection. CD8+ T cells
effectively clear MCMV from many organs (Reddehase et al., 1987). However,
viral clearance from the salivary gland is dependent on CD4+ T cells (Heise,
Connick, and Virgin, 1998; Lu et al., 2006). To determine the role of the adaptive
immune response in clearing RMvCXCL-1 CCMV and RMmCXCL1 from the
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Figure 16. Overexpression of host or viral chemokine only affects MCMV
dissemination to the salivary glands. hCXCR2 mice were inoculated with 106
PFUs of either RMmCXCL1 (Ñ), RMvCXCL1CCMV (D), RM4511 (

), or RM4503

(à ). Salivary glands were harvested 14 dpi and virus titers were determined by
plaque assay. Horizontal bars represent the mean virus titer (+/- standard
deviation). Results are from 5 mice and representative of 2 experiments.
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salivary gland, SCID mice were infected with recombinant or parental MCMVs.
Salivary glands were harvested at 14 dpi and titered. Even without an adaptive
immune response, no virus was recovered from salivary glands from mice
infected with recombinant viruses (Figure 17). RM4511 still disseminated to the
salivary glands. These data indicate that the absence of RMvCXCL-1CCMV and
RMmCXCL1 in the salivary gland was not due to an amplification of adaptive
immune response clearance.
Neutrophils are not responsible for the lack of recombinant viruses in the
salivary glands.
Both vCXCL-1CCMV and mCXCL1 bind and activate neutrophils via CXCR2
(Kobayashi, 2006; Miller-Kittrell et al., 2007). Overexpression of these
chemokines in the salivary gland may recruit and activate neutrophils triggering
an inflammatory response capable of clearing the recombinant viruses as they
disseminate there. To test this possibility, mice were depleted of neutrophils
using the neutrophil specific antibody 1A8 (anti-Ly6C) before infection with
RM4511, RMvCXCL-1CCMV, or RMmCXCL1.

At 14 dpi salivary glands were

titered (Figure 18). Even after depletion of neutrophils, no virus was recovered
from the salivary glands from mice infected with RMvCXCL-1CCMV or
RMmCXCL1.

Interestingly, there was a log decrease in virus titers in the

RM4511 infected mice. These results show that neutrophils are not responsible
for increased clearance from the salivary glands of chemokine expressing
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Figure 17. The adaptive immune response is not responsible for enhanced
clearance of RMvCXCL1CCMV and RMmCXCL1 in the salivary gland. SCID mice
were inoculated with 104 PFUs of RMmCXCL1, RMvCXCL1CCMV, or RM4511.
Salivary glands were harvested 14 dpi and virus titers were determined by
plaque assay. Horizontal bars represent the mean virus titer (+/- standard
deviation). Results are from 6 mice and represent one experiment.
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Figure 18. Neutrophils are not responsible for absence of RMmCXCL1 and
RMvCXCL1CCMV in the salivary gland. Mice were depleted of neutrophils using
anti-Ly6C antibody prior to inoculation with RMmCXCL1, RMvCXCL1CCMV, or
RM4511. Salivary glands were harvested 14 dpi and titered. Horizontal bars
represent the mean virus titer (+/- standard deviation) Results are from 5 mice
and are representative of 2 experiments. No virus was detected in any mice
infected with RMmCXCL1 or RMvCXCL1CCMV.
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MCMVs and that neutrophils have a minor role in the dissemination to the
salivary gland in MCMV infected mice.

Discussion
The CCMV chemokine homolog, vCXCL-1CCMV, was previously identified
as a functional chemokine, activating and recruiting human neutrophils similar to
the HCMV chemokine, vCXCL-1Tol. The in vivo function of, vCXCL-1CCMV is not
known and no CCMV model is presently available to study the contribution of this
protein to CCMV pathogenesis in its natural host. MCMV has been extensively
studied and current views of HCMV dissemination have come in part from
research in this model system (Edward S. Mocarski, 2007). MCMV has similar
tropism to HCMV. Specifically, both viruses undergo a cell-associated viremia
and virus can be recovered from myelomonocytic cells such as neutrophils,
monocytes, and their precursors (Bale and O'Neil, 1989; Saltzman, Quirk, and
Jordan, 1988). The mechanism and relative contribution of each cell type to viral
dissemination has not been sufficiently defined. Dissemination of MCMV to the
salivary gland is enhanced by the virally encoded chemokine, MCK2, while
spread to other organs occurs in a MCK2-independent manner (Saederup et al.,
2001). We reasoned that using RM4511, a mutated MCMV strain lacking MCK2,
to generate a MCMV expressing vCXCL-1CCMV would allow us to evaluate the
impact of vCXCL-1CCMV on virus dissemination. To determine if effects of vCXCL1CCMV on dissemination were unique to the viral chemokine or whether virally
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encoded host chemokines would produce comparable outcomes, we created
RMmCXCL1, a MCMV expressing mCXCL1, a homolog of hCXCL8 (IL8).
vCXCL-1CCMV and hCXCL8 were functionally similar when assessed in vitro
(Miller-Kittrell et al., 2007).
The dissemination pattern of RMvCXCL-1CCMV and RMmCXCL1 was
similar to RM4511 except in the salivary gland (Figure 16). Seeding of organs
such as the spleen, lymph node, and lung occurs following an initial low-level
viremia that is not affected by expression of MCK2 (Saederup et al., 2001).
Therefore, it was hypothesized that dissemination of the recombinant viruses to
these sites would follow a pattern similar to RM4511 independent of their
chemokine expression. Our data show that replication and clearance at the site
of inoculation is equivalent between the recombinants and the parental virus.
Likewise, primary dissemination is unaffected by expression of vCXCL-1CCMV or
mCXCL1. In contrast, both RMvCXCL-1CCMV and RMmCXCL1 were absent from
the salivary gland as late as 3 weeks post infection.
There are three possible explanations for the lack of recombinants in the
salivary glands. First, these viruses are unable to replicate in the salivary glands.
Other recombinants have shown a salivary gland growth defect (Manning et al.,
1992). We excluded this possibility because neither independently generated
recombinant was recovered from the salivary gland. The chance event of
affecting the salivary gland growth gene (sgg) in two separately isolated
recombinants makes this highly unlikely. We have also found that when mice are
treated with the anti mitotic drug, cyclophosphamide, which depresses the
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immune response, both recombinants can be titered in the salivary gland
(appendix 2). This demonstrates that both viruses can replicate in the salivary
gland and that the defect is in dissemination.
Second, overexpression of the chemokine could lead to an overactive
immune response resulting in increased clearance from the salivary gland. Our
data shows that in the primary organs, there are no differences in viral clearance
(Figure 16). If there was increased clearance from the salivary gland, elimination
of the adaptive immune response (Figure 17) and depletion of neutrophils (Figure
18) should have lead to recovery of the recombinant viruses from the salivary
glands. This minimizes this possibility.
Third, the chemokines could lead to a salivary gland dissemination defect.
When initially designing these recombinants, we expected that overexpression of
host or viral chemokines would lead to increased dissemination to the salivary
gland. To the contrary, overexpression of host or viral chemokine leads to no
dissemination to the salivary glands.

Since depletion of neutrophils did not

restore dissemination to the salary gland, another cell type that expresses
CXCR2 and is not depleted with the anti-Ly6C antibody would likely be
responsible. Our data cannot eliminate the possibility that this other cell type is
involved in clearance from the salivary gland or that normal dissemination to the
salivary gland is masked when this cell type is recruited and activated in the
primary organs. Our data implicate a cell of the myeloid lineage unless these
chemokines have an undefined interaction with a chemokine receptor present on
some other cell type. Although an exhaustive analysis of vCXCL-1CCMV receptor
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usage has not been completed, mCXCL1 receptor usage is well characterized
(Lee et al., 1995) and both have the same phenotype in our experiments.
Experiments are currently in progress using a mCXCR2-blocking antibody to
determine the role of CXCR2 in the clearance of RMmCXCL1. This antibody is
not appropriate for evaluating RMvCXCL-1CCMV since it will not block hCXCR2
but the two recombinants are likely cleared by a common mechanism and this
may be elucidated by study of RMmCXCL1 dissemination in the absence of
CXCR2.
Our data suggests that the inability to recover RMvCXCL-1CCMV and
RMmCXCL1 from the salivary gland, even in the absence of an adaptive immune
response or following neutrophil depletion, may be due to defective
dissemination of these recombinant viruses. MCMV encodes a number of gene
products that contribute to viral replication and dissemination to the salivary
gland. The sgg1 gene is important for MCMV replication in the salivary gland
although the mechanism for this is not known (Lagenaur et al., 1994). The
MCMV G protein-coupled receptor homolog, M33, is also needed for efficient
salivary gland replication based on mutagenesis studies (Case et al., 2008;
Davis-Poynter et al., 1997; Sherrill and Miller, 2006). Dissemination of MCMV to
the salivary gland is enhanced by the virally encoded chemokine, MCK2, while
spread to other organs occurs in a MCK2-independent manner. That MCMV has
so many genes regulating the spread and replication of the virus to the salivary
gland highlights the importance of this organ to MCMV biology, as it is both a site
of viral persistence and of transfer of virus from host to host (Ho, 1991; Shellam,
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2007). It also suggests MCMV may require unique mechanisms to facilitate
dissemination to and growth in the salivary gland as these genes have little to no
impact on the recovery of MCMV in other organs. However, the reasons for this
are unclear. Perhaps the cells of the salivary gland don’t adequately support viral
replication or the virus has difficulty gaining access to this site. The latter is
supported by the observation that MCK-2 dependent dissemination to the
salivary gland is associated with increased recruitment of myelomonocytic cells
to the inoculation site (Noda et al., 2006) suggesting viral spread to the salivary
gland is otherwise inefficient. Our continued work with RMvCXCL-1CCMV and
RMmCXCL1 may help better elucidate the mechanism of MCMV dissemination
to the salivary gland as well as provide a model for HCMV dissemination.
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Chapter 5
Conclusions
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The hypothesis of this study was that vCXCL-1CCMV is a functional CXC
chemokine that contributes to viral dissemination. To address this, we initially
compared the in vitro functional and biochemical characteristics of vCXCL-1 from
Toledo HCMV and CCMV in neutrophils. Neutrophils may be associated with the
pathobiology of HCMV infection. Neutrophilic infiltrates are found in AIDS
patients who have CMV related retinitis (Holland et al., 1983; Pepose et al.,
1985).

Furthermore,

HCMV

is

frequently

isolated

from

neutrophils

of

immunocompromised patients (Martin et al., 1984; Saltzman, Quirk, and Jordan,
1988; van der Bij et al., 1988a) and these cells are able to transmit infectious
virus (Saltzman, Quirk, and Jordan, 1988). Thus neutrophils may have a role in
disseminating HCMV.
The two primary CXC receptors on neutrophils are CXCR2 and CXCR1.
Since vCXCL-1Tol binds exclusively to CXCR2 (Penfold et al., 1999), we
measured binding of vCXCL-1CCMV to this receptor. vCXCL-1CCMV had a lower
affinity for human CXCR2 compared to vCXCL-1Tol and the host chemokine,
hCXCL1. This difference could reflect a difference in affinity of vCXCL-1CCMV for
human CXCR2 versus chimpanzee CXCR2. While known CXCR2 receptor
binding motifs are conserved in these two species, analyzing the binding of
vCXCL-1CCMV to CXCR2 on chimpanzee neutrophils would help address this
possibility. It is more likely that differences in the viral chemokines themselves
are responsible for the differences in binding affinity. This may be due in part to
the mutated ELR motif (LM) present in vCXCL-1CCMV or the variability within
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the N-loop region since both are important in receptor binding and signaling
(Clark-Lewis et al., 1991; Schraufstatter et al., 1993).
We measured calcium mobilization to evaluate vCXCL-1CCMV’s ability to
activate neutrophils. Remarkably, vCXCL-1Tol and vCXCL-1CCMV were found to
have similar activation potentials despite the mutation in the ELR sequence of
vCXCL-1CCMV. Mutations in this residue impair neutrophil activation by cellular
chemokines (Clark-Lewis et al., 1993). Nevertheless, vCXCL-1CCMV could not
completely desensitize neutrophils to hCXCL1. The lower binding affinity of
vCXCL-1CCMV likely contributes to this, since receptor desensitization is
determined in part by the binding affinity of the chemokine. In converse, hCXCL1
showed complete desensitization to vCXCL-1CCMV. hCXCL1 binds exclusively to
CXCR2, suggesting vCXCL-1CCMV activates only CXCR2 on neutrophils,
although we have not evaluated the ability of vCXCL-1CCMV to antagonize other
receptors.
We also examined activation of the ERK and Akt pathways by vCXCL1CCMV and vCXCL-1Tol. These pathways are important in chemokine-mediated
signaling that affect cell survival, expression of adhesion molecules, and
chemotaxis (Murphy, 2003). Interestingly, the activation of ERK and Akt signaling
was similar among the host and viral chemokines. This was surprising given that
vCXCL-1CCMV bound CXCR2 less efficiently than the other chemokines tested
and indicates that the crucial interactions between vCXCL-1CCMV and CXCR2
needed to induce these pathways are maintained.
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We analyzed vCXCL-1CCMV and vCXCL-1Tol in several functional assays to
identify mechanisms that might relate to the interaction of CMV with neutrophils
in vivo. vCXCL-1CCMV induces migration of neutrophils as does vCXCL-1Tol
(Penfold et al., 1999). This could enable CMV to modulate the immune response;
directly or indirectly recruiting cells that support viral replication or that facilitate
dissemination. Dissemination of MCMV to the salivary gland depends on
recruitment of myeloid progenitor cells by the viral chemokine, MCK2 (Noda et
al., 2006) and could be important to the pathogenesis of other CMVs.
vCXCL-1CCMV and vCXCL-1Tol were also found to suppress apoptosis in
neutrophils and upregulate members of the 2-integrin adhesion family, both of
which may contribute to viral dissemination. Inhibition of neutrophil apoptosis by
vCXCL-1CCMV and vCXCL-1Tol could aid virus dissemination by prolonging the
lifespan of CMV infected cells. The CMVs encode a number of proteins that
interfere with apoptosis (Andoniou and Degli-Esposti, 2006) and our data shows
the viral chemokines vCXCL-1CCMV and vCXCL-1Tol also interfere with this
process. Secretion of these chemokines could inhibit apoptosis in nonpermissive
cells such as neutrophils or monocytes that would not express the virally
produced anti-apoptotic proteins. 2-integrins are important in the adhesion and
extravasation of circulating neutrophils across the endothelium. HCMV infected
endothelial cells have been shown to transmit virus to neutrophils (Grundy et al.,
1998). Therefore, upregulation of 2-integrins might enhance the transmission of
CMV to neutrophils as well as facilitate the spread of infected cells to the tissues.
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Our in vitro findings provide circumstantial evidence for a role of vCXCL-1
in the activation and recruitment of neutrophils for CMV dissemination. We
initially evaluated vCXCL-1CCMV function in vivo using the MCMV mouse model.
Since the species specificity of the CMVs precludes the use of CCMV in the
mouse model, we generated recombinant MCMVs expressing either vCXCL1CCMV or the control host chemokine, mCXCL1.
In vivo, RMvCXCL1CCMV and RMmCXCL1 showed similar primary
dissemination to the lymph node, lung and spleen as the parental virus RM4511.
Recombinant virus was not recovered in the salivary glands at any time point
examined despite the detection of RM4511 within 7dpi. This was unexpected as
we anticipated that overexpression of host or viral chemokines would increase
dissemination to the salivary gland as seen with the MCMV chemokine, MCK2.
Since T cells play a large role in clearing MCMV, we evaluated
dissemination of RMvCXCL-1CCMV and RMmCXCL1 to the salivary gland in the
absence of the adaptive immune response. However, no virus was recovered
from the salivary glands of SCID mice infected with recombinant virus. Innate
immune cells, particularly natural killer cells, also help clear MCMV from various
organs (Shellam, 2007). However, it’s unlikely NK cells mediated clearance of
the recombinants from the salivary gland since NK cell induction would enhance
clearance of the recombinants in other organs as well. Since both vCXCL-1CCMV
and mCXCL1 activate neutrophils via CXCR2 (Kobayashi, 2006; Miller-Kittrell et
al., 2007), we considered that the recombinant virus defect was neutrophildependent. Interestingly, we found RM4511 salivary gland titers were reduced in
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neutrophil-depleted mice. This shows neutrophils have a role in the
dissemination of MCMV to the salivary gland. However, no recombinant virus
was recovered from the salivary glands of neutrophil-depleted mice. Therefore,
neutrophils are not responsible for the absence of RMvCXCL-1CCMV and
RMmCXCL1 in the salivary gland.
These

findings

suggest

RMvCXCL-1CCMV

and

RMmCXCL1

may

disseminate poorly to the salivary gland. Overexpression of vCXCL-1CCMV and
mCXCL1 may recruit a cell type that interferes with the normal dissemination of
MCMV. To begin to address this possibility we could examine the cellular
infiltrate at the site of virus inoculation to identify different cell types recruited by
RMvCXCL-1CCMV

and

RMmCXCL1

compared

to

the

parental

MCMV.

Alternatively, recombinant virus chemokine expression could alter cellular
trafficking such that virus is delivered to a salivary gland cell type that is not
permissive for replication.
In conclusion, this study is the first to characterize the CCMV viral
chemokine, vCXCL-1, and show it is functionally similar to vCXCL-1Tol.
Therefore, the study of vCXCL-1CCMV may contribute to a better understanding of
its HCMV homolog. Furthermore, this research is the first to evaluate the role of a
CMV CXC chemokine in vivo. Future work evaluating the role of other viral and
host chemokines in vivo using the mouse model will likely advance our
understanding of chemokines and their role in virus-host interactions.
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Appendix 1
Prokaryotic Expression of pUL146a
Introduction
The use of baculoviruses is well established for the expression of
recombinant proteins. This system allows for the post-translational modification
of many eukaryotic proteins including glycosylation, proper folding, and secretion
of proteins with signal sequences (Vialard, Arif, and Richardson, 1995).
Specifically, this system has been used to produce a number of different
chemokines and was the method used in generating the protein in this study,
vCXCL-1CCMV (Imai, 2000). However, attempts to express the related protein,
CCMV pUL146a, using the baculovirus system were unsuccessful. Although
recombinant baculovirus was generated as determined by infectious centers
assay, evidence of pUL146a secretion from insect cells was never detected by
silver stain or western blot analysis. It was considered that improper processing
of the signal sequence could lead to sequestration of the protein in the cell but
this possibility was eliminated when pUL146a was not detected in cell lysates.
Therefore, a prokaryotic expression system was chosen for the expression of
pUL146a.
While bacterial expression is fast and can produce high protein yields,
there are a number of shortcomings in expressing eukaryotic proteins. Proteins
produced by this method are not glycosylated, are not secreted, and can lack
disulfide bonds that would help in correct folding. Additionally, the production of
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large quantities of recombinant protein can result in the accumulation of
improperly folded protein in inclusion bodies within the cell (van Kimmenade et
al., 1988). Although pUL146a has no predicted glycosylations (data not shown),
the function of chemokines depends on a correctly folded protein, which is due in
part to the formation of disulfide bonds (Fernandez and Lolis, 2002).
Nevertheless, many bacterial expression systems have been engineered to allow
many of these modifications, including protein secretion, and formation of
disulfide bonds, among others. In fact, many commercially available chemokines
are manufactured using these systems. Therefore, in light of the failures in
expressing pUL146a in the baculovirus system, an E. coli based system was
tested for the expression of this protein.

Materials and Methods
Plasmids and Bacterial Strains
The E. coli strain AD494 (Novagen) was used for protein expression. This
bacterial strain allows disulfide bond formation due to a mutation in the
thioredoxin reductase gene that is maintained under kanamycin selection. The
UL146a gene was cloned into the pET-22b expression plasmid (Novagen).
Expression in pET-22b from the T7lac promoter is inducible allowing control of
the expression conditions. The ampicillin and kanamycin needed for selection
were used at a final concentration of 50 g/ml and 15 g/ml, respectively.
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Cloning of UL146a into E. coli strain AD494
Since cleavage of the signal sequence would not occur in AD494, primers
were designed to clone UL146a beginning at the first amino acid following the
predicted signal sequence cleavage site. The primers used were: pET24a+146a
F (NdeI)-5’gcgcgcgCATATGgtcacaagagaacaacactgt-3’ and CCMV UL146a 6His
(BamHI)-5’-cgGGATTCgttagtggtggtggtggtggtgtcctcccaggatagctac-3’. Cloning into
the NdeI site of pET22-b provides the initiating methionine needed for protein
expression. The PCR product was initially cloned into the pcrII vector (Invitrogen)
and sequenced to confirm the absence of mutations in the gene sequence. The
UL146a gene was subsequently cloned into the pET-22b plasmid following
restriction digest of both the UL46a fragment and pET-22b with NdeI and BamHI.
AD494 cells were made competent according to the protocol shown in Figure 19.
Finally, pET-22b+UL146a was transformed into AD494 cells using the standard
procedure for transformation of E. coli JM109 cells (Promega Technical Bulletin
TB095).

Following

verification

by

restriction

digest,

glycerol

stocks

of

transformants containing pET-22b+UL146a were stored at -80C for later use.
Induction of UL146a Expression
One day prior to induction a 15 ml culture of AD494-(pET-22b+UL146a)
was grown in LB broth with ampicillin and kanamycin to an OD600=0.7 and stored
at 4C, overnight. The following day, the starter culture was centrifuged to
remove the old media and the pellet was resuspended in fresh media. The starter
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Preparation of Competent Cells
1.

Inoculate 10 ml LB broth with a bacterial colony; grow overnight at 37ºC.

2.

Transfer 1-2 ml to 100 ml prewarmed LB broth and allow to grow at 37ºC
with shaking to OD600=0.5 (approximately 2-3 hours).
Divide culture into two tubes and centrifuge at 3000 rpm for 15 min at 4ºC.
Pour off supernatant and gently resuspend each pellet in 33 ml of Buffer
RF1.
Incubate tubes on ice for 20 min.
Centrifuge cells at 3000 rpm for 15 min at 4ºC.
Pour off supernatant and carefully add 5 ml of Buffer RF2 to each tube.
Resuspend pellet by gently swirling or rocking tube. Pellet will be loosely
distributed along entire side of centrifuge tube.
Incubate cells on ice for 15 min.
Place Eppendorf tubes on dry ice and distribute aliquots into tubes.
Place cells at –80ºC.

3.
4.
5.
6.
7.
8.
9.
10.
11.

Buffer RF1
Compound
Final Concentration Amount/liter Amount/200 ml
RbCl
100 mM
12.0 g
2.4 g
Mn2Cl-4 H2O
50 mM
9.9 g
1.98 g
Potassium Acetate
30 mM
30 ml
6.0 ml
(1 M stock, pH 7.5)
CaCl2-2 H2O
10 mM
1.5 g
0.3 g
Glycerol
15%
150 ml
30 ml
Adjust pH to 5.8 with acetic acid (~1 drop). Filter sterilize.

Buffer RF2
Compound
Final Concentration Amount/liter Amount/50 ml
MOPS
10 mM
20 ml
1 ml
(0.5 M stock, pH 6.8)
RbCl
10 mM
1.2 g
0.06 g
CaCl2-2 H2O
75 mM
11 g
0.55 g
Glycerol
15%
150 ml
7.5 ml
Adjust pH to 6.8 with 1 N NaOH (~1 drop). Filter sterilize.

Figure 19. Protocol for the preparation of competent bacteria.
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was used to inoculate 250 ml of fresh LB broth with antibiotics and grown at 37C
until an OD600 of 0.4-0.6. A preinduction sample was collected for later analysis.
Protein expression was induced by adding IPTG to the culture at a final
concentration of 1 mM and incubating for an additional 3-4 hours. Alternatively,
expression was induced with 0.5 mM IPTG at 37C or with 1 mM IPTG at 30C
as stated. Cells were harvested by centrifugation at 5,000 x g for 15 minutes. A
postinduction sample was removed for later analysis and the remainder of the
supernatant was discarded. The cell pellet was stored at -80C until protein
isolation.
Protein Purification
Frozen cell pellets were allowed to thaw on ice for 15 minutes prior to
purification. Otherwise, cell pellets were resuspended in 5 ml of lysis buffer. For
lysis under native conditions the lysis buffer contained 50 mM NaH2PO4, 300 mM
NaCl, and 10 mM imidazole, adjusted to pH 8. Lysis under denaturing conditions
used lysis buffer containing 100 mM NaH2PO4, 10 mM Tris-Cl, and 8 M urea,
adjusted to pH 8. The cells were lysed by sonication using six 30-second bursts
with a 30 second rest between each cycle. Lysates were centrifuged at 10,000 x
g for 20 minutes. To isolate soluble pUL146a, the supernatant was incubated
with Ni-NTA agarose beads at a ratio of 50 l of beads for each milliliter of
supernatant. Alternatively, to isolate insoluble protein from inclusion bodies a
refolding procedure was performed prior to incubation with the Ni-NTA beads.
The pellet was resuspended in 5 ml of denaturing buffer containing 5 M
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guanidine thiocyanate, 50 mM Tris (pH 8), 50 mM NaCl, 1 mM EDTA, and 10
mM mercaptoethanol and incubated for 1 hour. Forty-five ml of refolding buffer
(denaturing buffer without guanidine thiocyanate or mercaptoethanol) was slowly
added to the resuspended pellet using a peristaltic pump at a rate of 250
l/minute. Refolded protein samples were incubated with Ni-NTA beads as stated
above. Beads were washed with PBS and eluted using 500 mM imidazole when
performed under native or refolding conditions. To elute denatured proteins,
elution buffer of identical composition to the denaturing lysis buffer adjusted to
pH 4.5 was used. Protein samples were analyzed by either silver stain or western
blot analysis.

Results and Discussion
pUL146a was successfully expressed in AD494 cells. As shown in Figure
20, the protein was not present in pre-induced samples demonstrating the tight
regulation of this system and the absence of “leaky” expression prior to addition
of IPTG. Additionally, pUL146a was present in cells but not in the media
consistent with the inability of this protein to be secreted from bacterial cells.
However, attempts to purify pUL146a from cellular lysates under native
conditions failed. Therefore, it was considered that the protein detected in the cell
pellet might be contained within inclusion bodies. This was supported by the
detection of pUL146a in the insoluble fraction but not the supernatants following
lysis. Insoluble protein can result from several factors. First, disulfide bonds are
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Noninduced Induced

Figure 20. Expression of pUL146a in E. coli. Samples were collected pre- and
post-induction with IPTG. pUL146a was purified by incubation with Ni-NTA
agarose beads, run on a 15% SDS-PAGE gel, and silver stained.
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structurally important to chemokines and improper formation of these bonds
could result in an incorrectly folded protein. Although, E. coli AD494 has
amutation to prevent reduction of disulfide bonds other enzymes are present that
may have reducing potential (Prinz et al., 1997). Second, the high protein yield of
bacterial systems can also result in large amounts of unfolded or misfolded
proteins (Lilie, Schwarz, and Rudolph, 1998).

Modifications to the induction

protocol to decrease protein expression by slowing growth or decreasing the
amount of IPTG can sometimes improve recovery of protein from the soluble
fraction. Therefore, induction using 0.5 mM IPTG or incubation at 30C instead of
37C was tested in an attempt to improve the recovery of soluble pUL146a. The
altered induction conditions appeared to produce slightly lower protein yields
overall, however the protein was still largely insoluble (Figure 21). Since a
correctly folded protein was needed a refolding procedure was used in an
attempt to produce a renatured, functional protein (van Kimmenade et al., 1988).
Although the refolding procedure was attempted on numerous occasions
pUL146a was never identified in the refolded fraction (data not shown). The
refolding procedure consistently resulted in precipitate formation thus the proper
conditions for renaturation may not have been achieved.
Despite an inability to generate soluble pUL146a using the parameters
described, there are several additional modifications that could improve the
purification of properly folded protein using a bacterial expression system. First, a
different bacterial strain may be appropriate. Although use of AD494 can improve
disulfide bond formation, other E. coli strains are available that have mutations in
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Insoluble
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Soluble

Insoluble

Soluble
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0.5mM IPTG 1mM IPTG
37ºC
37ºC
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Figure 21. Induction of pUL146a expression. Bacterial cultures were induced
using the standard method (1mM IPTG, 37°C) or with lowered induction (O.5 mM
iPTG or 30°C) to evaluate the recovery of soluble protein by each method.
Samples were collected from each treatment, run on a 15% SDS-PAGE gel, and
silver stained.
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additional reductase genes. Use of these strains can further enhance the
formation of disulfide bonds resulting in better protein solubility (Bessette et al.,
1999). Alternatively, a cloning protocol that allows periplasmic localization
enhances folding of many proteins (Barth et al., 2000). A number of plasmids of
the pET series, including pET-22b, encode signal sequences that target the
expressed protein for transport to the periplasmic space. Additionally, inducing
protein expression under conditions of osmotic stress has been a successful
strategy for the periplasmic production of functional proteins (Blackwell and
Horgan, 1991). In the future, use of one or more of these strategies may be
needed to produce soluble pUL146a.
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Appendix 2
Evaluation of Recombinant MCMVs
Introduction
The dissemination pattern of RMvCXCL-1CCMV and RMmCXCL1 was
similar to RM4511 except in the salivary gland. Primary dissemination of MCMV
is not affected by expression of MCK2 (Saederup et al., 2001). Therefore, it was
hypothesized that dissemination of the recombinant viruses to these sites would
be similar to RM4511 independent of their chemokine expression. Our data show
replication at the inoculation site and primary dissemination is unaffected by
expression of vCXCL-1CCMV or mCXCL1. In contrast, both RMvCXCL-1CCMV and
RMmCXCL1 were absent from the salivary gland up to 3 weeks post infection.
To further characterize the salivary gland defect of the recombinant
MCMVs we depleted different inflammatory cells. Recombinant and parental
viruses were inoculated in Balb/c mice treated with cyclophosphamide.
Cyclophosphamide is an established, although not highly specific, method for
depleting neutrophils. Since both vCXCL-1CCMV and mCXCL1 activate neutrophils
via CXCR2 (Kobayashi, 2006; Miller-Kittrell et al., 2007), the recombinant virus
defect may be neutrophil-dependent. As an additional control, we evaluated virus
growth in Balb/c mice. Our previous studies were in hCXCR2 transgenic mice.
Without hCXCR2 present, we predicted RMmCXCL1 would maintain the salivary
gland defect using the endogenous mCXCR2 receptor while RMCXCL-1CCMV
would resemble RM4511 as the viral chemokine does not function via mCXCR2.
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Materials and Methods
Cyclophosphamide Treatment
In vivo depletion of granulocytes was performed by intraperitoneal
inoculation of 200L of cyclophosphamide (Sigma) per mouse. High dose
cyclophosphamide treatments (150mg/kg) were administered on days –5 and –1
prior to virus inoculation. Low dose cyclophosphamide treatments (100mg/kg)
were administered beginning on day 3 post-inoculation and continued every
three days until harvest. Verification of depletion was determined by FACS
analysis of peripheral blood cells stained with anti-GR-1 and anti-Mac-1
antibodies (Pharmingen) (Figure 22).
Recombinant Virus Infection of Balb/c Mice
106 PFUs of parental or recombinant virus was inoculated in the footpad of
Balb/c mice. The salivary glands were removed from the mice 14 days post
infection. Organs were weighed, sonicated in growth medium, and centrifuged at
400 X g to pellet debris. Supernatants were stored at -80C until titered.

Results and Discussion
Cyclophosphamide Restores Growth/Dissemination to the Salivary Gland
RMvCXCL-1CCMV and RMmCXCL1 were both recovered from the salivary
glands of mice following cyclophosphamide treatment (Figure 23).
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Figure 22. Depletion of neutrophils in cyclophosphamide treated mice. Peripheral
blood leukocytes were isolated from each mouse and stained with a 1:200
dilution of anti-GR-1 and anti-Mac-1 antibodies to verify the depletion of
neutrophils (Gr-1hi, Mac-1int).
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Figure 23. Cyclophosphamide treated mice show higher titers of RMvCXCL1CCMV
and RMmCXCL1 in the salivary gland. Mice were treated with cyclophosphamide
(CY) prior to inoculation with RMmCXCL1, RMvCXCL1CCMV, or RM4511. Salivary
glands were harvested 14 dpi and titered. Results are from 10 mice and
represent two experiments. P values were calculated using the student’s t-test
and are as follows: RM4511 (p= 0.096), RMvCXCL1CCMV (p= 0.112),
RMmCXCL1 (p= 0.105).
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Recombinant virus titers were lower than parental virus titers even with
cyclophosphamide treatment. This may be due to a defect in dissemination of
these viruses to the salivary gland, inefficient replication in this organ, or
clearance by cells in addition to neutrophils. This finding is in contrast to
neutrophil depletion studies. Neither recombinant could be detected in the
salivary gland of mice treated with 1A8 (Figure 18). This antibody is considered
more selective in depleting neutrophils (Daley et al., 2008) suggesting the
cyclophosphamide regimen depletes other cells besides neutrophils that clear
RMvCXCL-1CCMV

and

RMmCXCL1

from

the

salivary

gland.

Although

cyclophosphamide is often used to induce neutropenia, it is myelosuppressive
and some reports have shown cyclophosphamide decreases other cells of this
lineage (Zuluaga et al., 2006). In this scenario, cyclophosphamide depletes a
myeloid cell that is CXCR2 positive and responds to both vCXCL-1CCMV and
mCXCL1, contributing to clearance from the salivary gland.
Alternatively, cyclophosmamide treatment may facilitate dissemination of
the recombinant viruses to the salivary gland by recruiting a cell type capable of
trafficking to this organ. It has been noted that cyclophosphamide treatment
induces a late myeloid progenitor cell (Angulo et al., 2000; Pelaez et al., 2001).
This cell type is similar to the MCK2 induced cell type, which contributes to the
dissemination of the virus to the salivary gland (Noda et al., 2006). Therefore, the
absence of RMvCXCL-1CCMV and RMmCXCL1 in the salivary gland could result
from the inability of these viruses to recruit an appropriate cell for dissemination.
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Cyclophosphamide treatment induces a GR-1Int Mac-1hi population which allows
some dissemination of virus to the salivary gland.
Dissemination of RM4511 was not increased following cyclophosphamide
treatment. This is unexpected if the previous explanation were true. Previously it
was shown that MCK2 induces late myeloid progenitor cells (GR-1Int Mac-1hi)
(Noda et al., 2006) thus an increase in this population in cyclophosphamide
treated mice would be expected to increase dissemination of RM4511 to the
salivary gland. In contrast, RM4511 salivary gland titers decreased in mice
treated with cyclophosphamide and the anti-Ly6C antibody. Although not
significant, this decrease was consistently observed and could indicate that
neutrophils play a small role in the dissemination of MCMV to the salivary gland.
These data point to the complexity of MCMV dissemination, inducing some
inflammatory cells to aid dessemination to the salivary gland while avoiding the
detrimental effects of an overactive immune response.
Growth of Recombinant MCMV in Balb/c Mice
RM4511 titers were similar in the transgenic and Balb/c mice indicating
dissemination of RM4511 in the two mice strains is similar (Figure 24). However,
RMvCXCL-1CCMV and RMmCXCL1 were not recovered from the salivary gland of
Balb/c mice. It is expected that overexpression of vCXCL-1CCMV and mCXCL1
likely contributed to our inability to recover virus from the salivary gland thus the
cell type involved would likely express CXCR2. mCXCL1 can bind and activate
mCXCR2, a receptor present in both the transgenic and Balb/c mice. Thus the
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Figure 24. RMmCXCL1 and RMvCXCL1CCMV are not recovered from the salivary
glands of Balb/c mice. Balb/c mice were inoculated with 106 PFUs of
RMmCXCL1, RMvCXCL1CCMV, or RM4511. Salivary glands were harvested 14
dpi and virus titers were determined by plaque assay. Horizontal bars represent
the mean virus titer (+/- standard deviation). Results are from 5 mice and
represent one experiment.
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salivary gland defect should be evident in both mouse strains. In contrast, we
expected to recover RMvCXCL-1CCMV in the salivary gland of Balb/c mice. Since
vCXCL-1CCMV is unable to activate mCXCR2 based on analysis of calcium
mobilization, we expected this chemokine to be inactive in Balb/c mice. Our
finding that RMvCXCL-1CCMV was not recovered from the salivary gland of these
mice has several possible explanations. RMvCXCL-1CCMV could activate
mCXCR2 and our calcium mobilization data did not accurately show this.
Alternatively, RMvCXCL-1CCMV might activate a receptor other than CXCR2 that
is present in both mouse strains. Finally, the salivary gland defect could be
unrelated to chemokine expression and due to a currently unidentified difference
between the genomes of the recombinant and parental viruses.
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Appendix 3
Cytomegalovirus Immune Modulation
Introduction
After an initial primary infection herpesviruses establish latency for the life
of the host with periodic and spontaneous reactivation.

The coevolution of

herpesviruses with their host has provided an opportunity for these viruses to
evolve mechanisms to modulate the host immune response. While some virally
encoded proteins facilitate immune evasion, interfering with the hosts ability to
efficiently recognize and clear virus, others induce or alter specific immune
responses to benefit the viral life cycle. The herpesvirus family members,
cytomegaloviruses (CMVs), are no exception and encode numerous genes that
alter both innate and adaptive immune responses (Tables 2 and 3).

Innate Immune Responses
I. Complement Cascade
The complement system is composed of a number of plasma proteins that
induce inflammatory mediators, opsonize pathogens, and can lyse pathogens
and infected cells. The binding of complement proteins to antibody-antigen
complexes activates the classical complement pathway: bridging innate and
humoral immune responses. The alternative pathway is initiated by the binding of
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Table 2. Cytomegalovirus Modulation of Innate Immune Responses.
Protein

Gene

Virus

Function

Complement Cascade
Unknown

Unknown

HCMV
MCMV

Complement resistance

FC Receptor Homolog
gp34

TRL11/IRL11

HCMV

Function unknown

gp68

UL119-UL118

HCMV

Function unknown

fcr-1

m138

MCMV

 NK ligands H60 and MULT-1

Interferon-Mediated Immunity
IE1-p72

IE1

HCMV

Inhibits ISGF3

IE86

IE2

HCMV

 IFN expression

pp65

UL83

HCMV

 ISGs

M27

M27

MCMV

 STAT-2

m142/m143

m142/m143

MCMV

 PKR activity

TRS1/IRS1

TRS1/IRS1

HCMV

 PKR activity

Natural Killer Cells
gpUL18

UL18

HCMV

MHC I homolog; alters NK cell
function

gpUL142

UL142

HCMV

MHC I homolog;  NK cell function

gpUL141

UL141

HCMV

 CD155 expression

gpUL16

UL16

HCMV

 NK cell function

UL40 peptide

UL40

HCMV

 NK cell function

m157

m157

MCMV

MHC I homolog;  NK cell function

m144

m144

MCMV

MHC I homolog;  NK cell function

gp40

m152

MCMV

 NK ligands of the RAE-1 family

m145

m145

MCMV

 NK ligand MULT-1

m155

m155

MCMV

 NK ligand H60

Cytokine Homologs
cmvIL-10

UL111

HCMV
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Induces anti-inflammatory response

Table 2. Continued.
Protein

Gene

Virus

RhcmvIL-10

RhCMV

Function
Induces anti-inflammatory response

Cytokine Receptor Homologs
UL144

UL144

MCMV

Blocks T cell proliferation

Viral Chemokine Homologs
vCXCL-1

UL146

HCMV

Activates neutrophils

vCXCL-1

UL146

CCMV

Activates neutrophils

pUL147

UL147

HCMV

Function unknown

pUL128-131

UL128-131

HCMV

Mediate viral entry/cell tropism

MCK2

m129/131

MCMV

 salivary gland dissemination

pr131

r131

RCMV

 salivary gland dissemination

Unknown

GpCMV

Activates HCCR-1

GPCMV-MIP

Chemokine Receptor Homologs
pUS28

US28

HCMV

Constitutive signaling; binds
chemokine

pUS27

US27

HCMV

Function unknown

pUL33

UL33

HCMV

Constitutive signaling

pR33

R33

RCMV

Needed for salivary gland replication

pM33

M33

MCMV

Needed for salivary gland replication

pUL78

UL78

HCMV

Function unknown

pR78

R78

RCMV

Function unknown

pM78

M78

MCMV

Function unknown

Chemokine Binding Proteins
pUL21.5

UL21.5

HCMV

Binds CCL5

Apoptosis
vICA

UL36

HCMV

Inhibits extrinsic apoptosis

vMIA

UL37x1

HCMV

Inhibits intrinsic apoptosis

m38.5

m38.5

MCMV

Inhibits apoptosis

M45

MCMV

Inhibits death receptor signaling

M45
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Table 3. Cytomegalovirus Modulation of Adaptive Immune Responses.

Protein

Gene

Virus

Function

T Cell Mediated Immunity
gpUS3

US3

HCMV

Inhibits MHC I and II expression

gpUS2

US2

HCMV

MHC I and II degradation

gpUS11

US11

HCMV

MHC I degradation

gpUS6

US6

HCMV

Inhibits TAP peptide transport

gpUS8

US8

HCMV

Binds MHC I molecules

gpUS10

US10

HCMV

Binds MHC I molecules

gp48

m6

MCMV

Targets MHC I to lysosomes

gp40

m152

MCMV

MHC I retention in the ERGIC

gp34

m4

MCMV

 MHC I intracellular retention
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complement proteins directly to the surface of pathogens. Antibody-mediated
complement lysis is an important mechanism for elimination of virus-infected
cells. Therefore, a number of viruses encode complement regulatory proteins.
Herpes simplex virus 1 (HSV-1) and Epstein Barr virus (EBV) both have
homologs of regulators of complement activation (RCA) proteins, such as CD46
and CD55 (Tortorella et al., 2000). Complement control proteins including CD46,
CD55, and CD59 inhibit complement activation by regulating various stages
within the complement cascade (Hirsch, 1982). While no cytomegalovirus
encoded RCA homologs have been identified, cytomegaloviruses (CMVs) have
evolved mechanisms for limiting complement activity. HCMV incorporates cellular
CD55 and CD59 into the virion. Blocking CD55-mediated complement
inactivation with antibodies decreases HCMV replication in fibroblast cell lines
following stimulation with complement proteins (Spear et al., 1995). HCMV also
upregulates expression of CD46 and CD55 on the surface of infected cells which
decreases the accumulation of C3 convertases and protects the cells from
complement mediated lysis (Spiller et al., 1996). Although the mechanisms differ
from other herpesviruses, HCMV is able to induce complement inactivation.
MCMV also induces CD46 expression on infected fibroblasts. This
upregulation was mapped to a CMV responsive element within the CD46
promoter (Nomura et al., 2002). Although mice typically express the complement
regulator CRRY instead of CD46 (Holers, Kinoshita, and Molina, 1992), CD46
expression was sufficient to decrease complement-mediated lysis of MCMV
infected cells (Nomura et al., 2002). Viral manipulation of complement regulatory
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proteins may explain the resistance of CMV infected fibroblasts to complement
lysis when treated with virus specific antibodies which would be expected to
induce the classical complement pathway (Spiller et al., 1997). Although virally
infected cells are resistant to complement-mediated lysis, the specific viral
proteins that interfere with complement activity during CMV infection have not
been identified.
II. Fc Receptor Homologs
Clinical evidence supports a role for antibodies in limiting cytomegalovirus
infection. The ability to modulate antibody-mediated immunity would therefore
benefit

cytomegalovirus

pathogenesis.

CMV

infected

cells

can

bind

immunoglobulins in serum of seronegative individuals (Keller et al., 1976;
Rahman et al., 1976; Westmoreland, St Jeor, and Rapp, 1976). This
phenomenom was linked to the expression of Fc binding proteins (FcBP) on the
surface of infected cells and are specific for IgG but not other Ig isotypes
(Furukawa et al., 1975; Xu et al., 1989). Two HCMV FcBP have been identified,
gp34 and gp68, which are encoded by the genes TRL11/IRL11 and UL119UL118, respectively (Atalay et al., 2002; Lilley, Ploegh, and Tirabassi, 2001).
Both proteins have homology to cellular Fc receptors (FcR). Normally the FcRs
from the host interact with the Fc region of Igs and mediate a number of effector
functions including phagocytosis, release of inflammatory cytokines, and natural
killer (NK) cell antibody mediated cellular cytotoxicity (ADCC) (Ravetch and
Bolland, 2001). It has been spectulated that anti-viral antibody’s Fc region binds
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the viral FcR instead of host FcRs, blocking antiviral activities. Although the
viral FcR from HSV-1 (gE-gI) protects infected cells in vitro from ADCC and
complement activation (Dowler and Veltri, 1984; Dubin et al., 1994) and HSV-1
mutants lacking gE-gI had lower titers in mice (Peng et al., 1998), the function of
the HCMV-encoded FcR has not been determined. Recently it was shown that
the HCMV FcRs interact with IgG differently than HSV-1 gE-gI and host FcRs
suggesting the HCMV encoded proteins may have unique functions (Sprague et
al., 2008).
MCMV encodes an unrelated FcR, fcr-1 or m138. Although, m138 has no
homology to the HCMV FcRs it has some conserved structural features with
cellular FcRs and gE-gI (Thale et al., 1994). m138 is important for MCMV
replication in vivo. Both wild-type and B cell deficient mice infected with a m138
mutant MCMV had lower viral titers in several organs compared to wild-type
MCMV, thus impaired growth of MCMV is not due to an enhanced humoral
immune response in the absence of m138 (Crnkovic-Mertens et al., 1998; Jonjic
et al., 1994). Interestingly, m138 downregulates expression of H60 and MULT-1,
two ligands of the activating NK receptor, NKG2D. The importance of this
downregulation in vivo was demonstrated by the ability of m138 MCMV to grow
like wt MCMV in mice depleted of NK cells. The downregulation of MULT-1, but
not H60, is due to defective cellular trafficking that results in degradation of the
protein (Lenac et al., 2006). m138 also decreases cell surface trafficking of the
costimulatory molecule B7-1 on dendritic cells (DCs), interfering with the ability of
179

these cells to activate antigen specific T cells (Mintern et al., 2006). Thus the
MCMV FcR broadly affects both the innate and adaptive arms of the immune
response, although probably not in the same manner as HSV-1 gI-gE.
III. Interferon-Mediated Immunity
Although interferons (IFNs) are induced early during CMV infection (Boyle,
Pietropaolo, and Compton, 1999; Zhu, Cong, and Shenk, 1997), these viruses
encode a number of proteins that interfere with and mitigate the effects of their
activation (Aitken et al., 1999). The type I interferons IFN and IFN are part of
the innate immune response to viral infections. The binding of IFN and IFN to
the IFN receptor induces Jak/Stat signaling leading to the rapid upregulation of
interferon-stimulated genes (ISGs), such as MHC class I molecules and various
cytokines (Muller et al., 1994). Two HCMV immediate early gene products,
72kDa immediate early 1 (IE1) protein (IE1-p72) and IE2 protein (IE86), interfere
with IFN signaling. IE1-p72 inhibits the ISG transcriptional activator, ISGF3, from
binding to the ISG promoter (Paulus, Krauss, and Nevels, 2006). IE86 blocks
binding of the transcription factor NFB to the IFN promoter and leads to the
downregulation of IFN expression in HCMV infected fibroblasts (Taylor and
Bresnahan, 2005; Taylor and Bresnahan, 2006).
The HCMV tegument protein pp65 (UL83) also blocks interferon activity,
acting early during infection prior to transcription of the immediate early gene
products (Browne et al., 2001). Microarray analysis has revealed pp65
downregulates numerous ISGs although the mechanism for this is unclear
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(Abate, Watanabe, and Mocarski, 2004). Conflicting reports have attributed this
decrease to interference with either NFB activity or another transcriptional
regulator, IRF-3, although both authors suggest pp65-mediated defects in
nuclear localization of the transcription factors likely contribute to the decreased
activity (Abate, Watanabe, and Mocarski, 2004; Browne and Shenk, 2003). The
conservation of UL83 within CMV genomes and the in vivo attenuation of an
MCMV lacking expression of the murine pp65 homolog (Morello, Cranmer, and
Spector, 1999) illustrates the importance of pp65 for CMV survival. A virion
constituent of rhesus CMV (rhCMV) also blocks interferon activation but this was
not due to a UL83 homolog (DeFilippis and Fruh, 2005).
The MCMV encoded protein, M27, interferes with both type I and type II
(IFN) interferon activity by downregulating the signaling molecule, STAT2
(Abenes et al., 2001; Zimmermann et al., 2005). M27 decreases transcription of
constituents of the immunoproteasome. This IFN inducible proteasome
enhances MHC class I processing of peptides for presentation (Khan et al.,
2004b). Therefore, M27 may not only protect MCMV from the direct antiviral
effects of interferon induction but also interfere with presentation of viral peptides
to CD8+ T cells, a common theme to be discussed below.
MCMV and HCMV also encode proteins that interact with interferon
induced gene products (Roy and Mocarski, 2007). The MCMV gene products
m142 and m143 decrease activation of protein kinase R (PKR) (Valchanova et
al., 2006), an enzyme that blocks protein synthesis in infected cells leading to
impairment of viral replication. PKR is activated via dsRNA, which is produced
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during transcription of complementary strands of the CMV genome. Both m142
and m143 have dsRNA binding domains and may interfere with the binding of
PKR with dsRNA, preventing its activation (Child et al., 2006). The HCMV
encoded proteins TRS1 and IRS1 also have dsRNA binding capabilities (Hakki
and Geballe, 2005; Hakki et al., 2006). Both proteins inhibit PKR function in
vaccinia virus (VV) infected cells but their role in HMCV infection has not been
evaluated (Child et al., 2004).
IV. Natural Killer Cells
Natural killer (NK) cells are cytotoxic cells of the innate immune response
that play an important role in eliminating virus-infected cells early during infection.
Signaling induced via both activating and inhibitory receptors regulates the
cytotoxic activity of NK cells. Inhibitory receptors recognize certain MHC I alleles
whereas a number of ligands can bind activating receptors to trigger NK cell
mediated killing. NK cells are important for controling cytomegalovirus infections
both in mice and humans (Bukowski et al., 1985; Gazitt, 2004). Therefore, it is
not surprising the cytomegaloviruses encode numerous proteins that interfere
with NK cell activity.
HCMV encodes several proteins that interact with and alter NK cell
responses. One of the earliest identified proteins, gpUL18, is encoded by the
gene UL18 and is a MHC class I homolog (Beck and Barrell, 1988). gpUL18
binds the 2-microglobulin (2m) and unlike the MHC homolog of MCMV, m144,
gpUL18 also binds endogenous peptide (Browne et al., 1990; Fahnestock et al.,
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1995). gpUL18 binds the NK cell inhibitory receptor LIR-1 with higher affinity than
host MHC I molecules (Cosman et al., 1997; Occhino et al., 2008; Yang and
Bjorkman, 2008). However, the function of gpUL18 has not been clearly defined.
gpUL18 expression both inhibits and activates NK cells in vitro and activates LIR1- cells further implicating complex mechanisms for NK cell modulation (Kim et
al., 2004; Leong et al., 1998; Prod'homme et al., 2007; Reyburn et al., 1997;
Wagner et al., 2007). Furthermore, clinical isolates of HCMV express pUL18
variants with different LIR-1 binding affinities (Cerboni et al., 2006; Garrigue et
al., 2007) that may have differential functions in vivo. In addition to its effect on
NK cells, gpUL18 was recently shown to inhibit dendritic cell maturation and
migration. While dendritic cells express LIR-1, whether this receptor mediates the
effect of gpUL18 on dendritic cell activity was not determined (Wagner et al.,
2008). Collectively, current data suggests gpUL18 may impact the function of
several cell types in vivo that may partially relate to its ability to bind and activate
LIR-1.
Recently, it was found the UL142 gene encodes a second HCMV MHC I
homolog (Davison et al., 2003). Cells expressing gpUL142 are protected from NK
cell lysis. However, this effect was not evaluated in the context of HCMV infection
(Wills et al., 2005). While the mechanism of this effect has yet to be determined,
gpUL142 was recently shown to downregulate MICA, a ligand for the activating
NK cell receptor, NKG2D (Chalupny et al., 2006).
Some HCMV encoded proteins alter expression of NK cell receptor
ligands. The protein product of UL141, gp141, decreases the expression of
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CD155, a ligand for NK cell activating receptors. A common theme in CMV
immune modulation, gp141 inhibits CD155 transport to the cell surface (Tomasec
et al., 2005). This downregulation inhibits NK cell activity in vitro but further
information regarding its function and impact in vivo remain to be answered.
The UL16 encoded glycoprotein, gpUL16, binds a number of ligands of
the NK cell activating receptor, NKG2D. gpUL16 binds members of the UL16binding protein (ULBP) and MIC family of proteins, which are NK ligands that are
activated under conditions of cell stress (Sutherland, Chalupny, and Cosman,
2001). In particular gpUL16 binds to ULBPs 1 and 2 (Cosman et al., 2001; Kubin
et al., 2001) and MICB (Wu et al., 2003). gpUL16 downregulates these proteins,
retaining them intracellularly in the ER or golgi network (Dunn et al., 2003; Rolle
et al., 2003; Vales-Gomez et al., 2006). The interaction of gpUL16 with these
ligands blocks NK cell activation in vitro (Kubin et al., 2001; Odeberg et al., 2003;
Sutherland, Chalupny, and Cosman, 2001; Welte et al., 2003) and may represent
a way for HCMV to inhibit the activation of NK cells due to replication induced cell
stress.
Interestingly, HCMV increases expression of the non-classical MHC I
molecule, HLA-E, while downregulating expression of many other MHC I alleles
(Wang et al., 2002). This upregulation is due to the expression of UL40, a HCMV
encoded protein that contains a peptide sequence identical to the leader peptide
bound by HLA-E (Cerboni et al., 2001; Tomasec et al., 2000; Ulbrecht et al.,
2000). Therefore, UL40 increases expression of HLA-E independent of TAP
mediated peptide processing, which is inhibited during infection by the HCMV
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encoded protein, gpUS6 (Lehner et al., 1997). HLA-E is a ligand for the inhibitory
receptor CD94/NKG2A and the UL40 induced upregulation of HLA-E protects
HCMV infected cells from NK cell lysis (Wang et al., 2002).
MCMV encodes two homologs of MHC class I molecules, although
neither has similarity to the HCMV homolog, UL18 (Cavanaugh et al., 1996;
Rawlinson, Farrell, and Barrell, 1996). The MCMV gene m157 has low sequence
homology to MHC class I molecules but structural analysis shows it has features
similar to MHC like folds (Arase et al., 2002). m157 is expressed on infected cells
tethered by a gycosylphosphatidylinositol (GPI) anchor (Davis et al., 2008). m157
binds the NK receptor, Ly49H, a member of the Ly49 family of inhibitory
receptors (Arase et al., 2002; Kielczewska et al., 2007). Interestingly, the m157Ly49H interaction activates NK cells in vitro inducing NK cell cytotoxicity and
cytokine and chemokine expression (Dorner et al., 2004; Smith et al., 2002).
m157 activation of Ly49H is sufficient to override NK cell inhibition in cells
expressing MHC I (Adams et al., 2007). Mice infected with a MCMV mutant
lacking m157 are more susceptible to MCMV infection and have decreased NK
cell activity (Bubic et al., 2004). Furthermore, MCMV replicates to higher titers in
mouse strains that lack expression of Ly49GH receptors (Daniels et al., 2001),
demonstrating the importance of this interaction to immune protection against
MCMV. Although Ly49H protects against MCMV in laboratory mice, wild isolates
of MCMV have m157 variants that fail to activate NK cells (Voigt et al., 2003).
Mutations in m157 were also shown to accumulate following passage of MCMV
in mice indicating a strong selective pressure in favor of m157 variants that inhibit
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NK cell activation. This is further supported by the finding that m157 also binds
the inhibitory NK receptor, Ly49I (Arase et al., 2002). Furthermore, m157 was
recently shown to induce the functional impairment of some NK cell populations
(Sun and Lanier, 2008; Tripathy et al., 2008). Therefore, activation of NK cells by
m157 likely occurs less frequently in natural infection of mice.
m144 is another MCMV encoded MHC I homolog (Hanson et al., 1999;
Rawlinson, Farrell, and Barrell, 1996). m144 is expressed on the cell surface
despite its inability to bind endogenous peptides (Chapman and Bjorkman,
1998). m144 can inhibit NK cell cytolysis in vitro (Cretney et al., 1999),
suggesting it serves as a decoy receptor to inhibit NK cell activation. Consistent
with this idea, MCMV mutants without m144 expression grow poorly in mice due
to enhanced NK cell activation (Farrell et al., 1997). While a flexible region within
m144 that could potentially interact with host receptors has been identified
(Natarajan et al., 2006), m144 has not been shown to bind any cellular receptor
and its exact function remains unknown (Cretney et al., 1999).
MCMV also encodes three proteins that downregulate ligands of the NK
cell activating receptor, NKG2D. The protein encoded by m145 decreases
expression of MULT-1 (Krmpotic et al., 2005), the m155 encoded glycoprotein
downregulates H60 (Lodoen et al., 2004), and the m152 encoded glycoprotein
(gp40) downregulates proteins of the RAE-1 family (Krmpotic et al., 2002;
Lodoen et al., 2003). MCMV mutants lacking any one of these genes are
attenuated in vivo and NK cell depletion restores MCMV growth. These results
support a role for these proteins in inhibiting NK cell mediated clearance (Abenes
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et al., 2004; Hasan et al., 2005; Krmpotic et al., 2002; Krmpotic et al., 2005).
Although the exact mechanism of action is not known for these proteins, both
m155 and gp40 act at a post-transcriptional step and likely interfere with
trafficking of proteins to the cell membrane (Hasan et al., 2005; Krmpotic et al.,
2002; Lodoen et al., 2004).
V. Cytokine Homologs
Interleukin-10

(IL-10)

is

an

immunosuppressive

cytokine

that

downregulates inflammatory cytokine synthesis and interferes with antigen
presentation by decreasing expression of MHC class II on antigen presenting
cells (Moore et al., 2001). Members of the poxvirus and herpesvirus families,
including some cytomegaloviruses, encode IL-10 homologs (Redpath, Ghazal,
and Gascoigne, 2001). In contrast to other viral IL-10 homologs that have high
similarity (80%) to their host IL-10, the HCMV IL-10 protein (cmvIL-10) has only
limited homology to human IL-10 (hIL-10) (Kotenko et al., 2000). cmvIL-10 binds
the IL-10 receptor (hIL-10R) albeit with lower affinity than hIL-10 (Kotenko et al.,
2000; Spencer et al., 2002). Nevertheless, it retains the capacity to induce a
strong anti-inflammatory response. cmvIL-10 downregulates expression of IFN
and TNF in peripheral blood mononuclear cells (PBMCs) and decreases
expression of both MHC I and II on PBMCs and DCs (Chang et al., 2004; Raftery
et al., 2004; Spencer et al., 2002). DCs exposed to cmvIL-10 inefficiently
stimulated T cell proliferation (Chang et al., 2004) supporting its role in immune
suppression. cmvIL-10 activates the phosphotidylinositol 3-kinase pathway
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leading to inhibition of cytokine production (Spencer, 2007). Interestingly, cmvIL10 shows none of the stimulatory functions of hIL-10 such as promoting B cell
differentiation or CD8+ T cell proliferation and thus may have retained only the
immunosuppressive functions beneficial to viral replication in the host (Redpath,
Ghazal, and Gascoigne, 2001). cmvIL-10 also alters function of non-leukocyte
populations and was shown to interfere with placental cytotrophoblast behavior.
Exposure of cytotrophoblasts to cmvIL-10 interfered with cytotrophoblast invasion
,which could affect placental development leading to the sequelae observed
following congenital CMV infections (Yamamoto-Tabata et al., 2004).
An alternatively spliced version of cmvIL-10 was originally identified during
latent HCMV infection and termed latency associated cmvIL-10 (LacmvIL-10)
(Jenkins, Abendroth, and Slobedman, 2004). However, this transcript is also
expressed during productive infection (Jenkins et al., 2008a). LacmvIL-10 fails to
induce signaling pathways associated with IL-10R which implies LacmvIL-10 may
not bind to IL-10R or, at least, differentially activates this receptor. LacmvIL-10
also decreases MHC II expression on granulocyte-macrophage progenitors (GMPs) and monocytes, both sites of CMV latency, possibly limiting clearance of
latently infected cells (Jenkins et al., 2008b).
A number of primate CMVs encode proteins similar to IL-10 (Lockridge et
al., 2000) but only the function of the rhesus CMV (RhCMV) homolog has been
evaluated to date. RhcmvIL-10 downregulates cytokine expression in PBMCs
and MHC II molecule expression in monocytes (Spencer et al., 2002). Therefore,
the function of human cmvIL-10 is conserved in RhCMV infection. Interestingly,
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chimpanzee cytomegalovirus (CCMV) and MCMV do not encode IL-10 homologs
(Lockridge et al., 2000). MCMV infection induces cellular IL-10 expression
providing a mechanism for immune interference in the absence of a virally
encoded IL-10 protein (Redpath et al., 1999). Therefore, IL-10 immune
suppression, whether cellular or viral in origin, likely creates an environment that
supports efficient viral replication in the host.
VI. Cytokine Receptor Homologs
The HCMV gene, UL144, encodes a protein with limited homology to the
herpes simplex virus entry mediator (HVEM), a member of the tumor necrosis
factor receptor (TNFR) superfamily (Benedict et al., 1999). UL144 is the only
TNFR homolog identified to date in herpesviruses. The UL144 protein does not
bind any known TNF ligand (Benedict et al., 1999; Lurain et al., 1999; Poole et
al., 2006). UL144 has only been shown to bind a member of the Ig superfamily, B
and T lymphocyte attenuator (BTLA) (Cheung et al., 2005), also a ligand of
HVEM (Sedy et al., 2005). Binding of UL144 to BTLA blocks T cell proliferation
and could impair lymphocyte responses to HCMV (Cheung et al., 2005). UL144
activates TNFR-activated factor (TRAF6) leading to NFB activation and
upregulation of the chemokine CCL22 (Poole et al., 2006). CCL22 is a
chemoattractant of Th2 and regulatory T cells. Activation and attraction of these
cells may help HMCV evade T cell-mediated antiviral activity. UL144 is located in
the UL/b’ region of HCMV, a portion of the genome thought to encode potential
virulence factors. Different UL144 genotypes have been identified in clinical
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isolates however, all but one report have found no association between the
different genotypes and CMV disease (Arav-Boger et al., 2006a; Arav-Boger et
al., 2002; Bale et al., 2001; Heo et al., 2008; Lurain et al., 1999; Mao et al., 2007;
Picone et al., 2005; Yan et al., 2008). Although there is much speculation on the
role that UL144 plays in immune modulation, its role in CMV pathogenesis and
survival in vivo is still unclear.
VII. Viral Chemokine Homologs
HCMV encodes two ORFS with homology to CXC chemokines, UL146
and UL147 (Cha et al., 1996). While no functional data is available for UL147,
analysis of the protein product of UL146, vCXCL-1, demonstrated its capacity as
a functional chemokine. vCXCL-1 was shown to bind exclusively to hCXCR2 with
an affinity similar to that of the host chemokine, CXCL8. Additionally, vCXCL-1
was able to induce chemotaxis and intracellular calcium release in human
neutrophils, again to levels comparable to host chemokines (Penfold et al.,
1999).
Chimpanzee CMV encodes homologs of UL146 and UL147 as well as the
related gene UL146a. However, only the product of UL146 has been evaluated
thus far. VCXCL-1CCMV induced chemotaxis and calcium release in human
neutrophils. Additionally, it was shown to increase expression of adhesion
molecules on the surface of neutrophils and reduce apoptosis in these cells
(Miller-Kittrell et al., 2007). Taken together, the function of the HCMV and CCMV
vCXCL-1s in vitro suggest the potential for these viral chemokines to alter the
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response of neutrophils in the course of CMV infection. A mutant HCMV virus
with a deletion of UL146-UL147 was unable to infect neutrophils but retained its
ability to infect other cells providing additional evidence these proteins facilitate
an interaction of CMV with neutrophils (Hahn et al., 2004).
Due to the strict species specificity of CMV, in vivo characterization of
UL146 and UL147 has been limited to sequence analysis of clinical HCMV
isolates. UL146 is highly variable, differing as much as 60% among isolates (Heo
et al., 2008). It was postulated that this variability might correlate with the severity
of CMV disease however no clear relationship has been identified (Arav-Boger,
Zong, and Foster, 2005; Bale et al., 2001; Bradley et al., 2008; Hassan-Walker et
al., 2004). It was recently suggested the variability of UL146 may have arisen in
early human populations and does not likely contribute to the pathogenesis of
congenital infection (Bradley et al., 2008).
HCMV also encodes genes with limited homology to CC chemokines.
UL128 and UL130 both have signal sequences and conserved cysteine motifs
similar to CC chemokines (Akter et al., 2003). It has yet to be determined
whether these proteins function as chemokines. Interestingly, the UL128-131
locus was found to be necessary for endothelial cell and leukocyte tropism based
on the inability of HCMV UL128-131 deletion mutants to infect these cell types
(Hahn et al., 2004). This likely explains the loss of endothelial cell tropism in labadapted strains of HCMV, a number of which were shown to have deletions or
mutations in at least one gene from this region (Akter et al., 2003). The UL128131 proteins have recently been shown to interact with gH/gL complexes that
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mediate entry of CMV into endothelial and epithelial cells, in contrast to the
gH/gL/gO complexes that mediate virus entry into fibroblasts (Wang and Shenk,
2005a; Wang and Shenk, 2005b).
The best characterized of the CMV chemokines is the CC chemokine
homolog of MCMV. Originally identified as the m131 gene product, MCK1,
transcript analysis during MCMV infection determined that a spliced product of
m131 and m129, referred to as MCK2 was the only transcript identified from this
locus. The CC chemokine domain is confined to the MCK1 coding region and is
followed by a long carboxy-terminal domain (199 amino acids) with no known
homology,

making

MCK2

considerably

longer

than

other

chemokines

(MacDonald et al., 1999; MacDonald, Li, and Virgin, 1997). In contrast to UL146,
the DNA sequence of MCK2 is highly conserved in isolates from wild mice
(Smith, Shellam, and Redwood, 2006).
Initial studies in vitro showed MCK1 induced higher levels of Ca2+
mobilization in peritoneal exudates cells from MCMV infected mice than cells
from uninfected mice. This demonstrates that MCK1 could activate cells recruited
to the site of MCMV infection (Saederup et al., 1999). MCK2 is important for viral
spread within the host. When a recombinant MCMV with mutations in the m131
gene generated via point mutations or insertions was inoculated into mice, these
recombinants showed a defect in dissemination to the salivary gland. Mice
infected with these mutants developed less inflammation at the site of
inoculation, reduced secondary viremia, as well as lower viral titers in the salivary
glands, a site of dissemination following secondary viremia (Fleming et al., 1999;
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Saederup et al., 2001). This was the first direct evidence that a CMV encoded
chemokine is important for the dissemination of the virus in its host. Additional
work identified the MCK2-recruited cell type as a late myeloid progenitor,
consistent with reports that CMV infects and can remain latent in cells of the
myelomonocytic lineage (Noda et al., 2006).
Rat CMV (RCMV) encodes a CC chemokine with similarity to both m131
and m129, having N-terminal chemokine homology and a long carboxy-terminus
like that of MCK2 (Vink, Beuken, and Bruggeman, 2000). Rats infected with
RCMV deletion mutants lacking pr131 expression had reduced viral loads in the
spleen and salivary glands. Additionally these mice had reduced swelling and
macrophage infiltration at the site of virus inoculation (Kaptein et al., 2004).
Therefore, the r131-encoded protein, pr131, appears to be a functional homolog
of MCK2.
Guinea pig CMV (GPCMV) has one gene with homology to CC
chemokines, though it lacks positional or sequence similarity to the m131/m129
genes of MCMV. GPCMV-MIP is most similar to the cellular chemokines,
CCL3/CCL4 (MIP-1/) and CCL14 (HCC-1). GPCMV-MIP induced Ca2+ flux
and migration of cells expressing HCCR-1 but did not elicit a response from cells
expressing other CC receptors. CCL14 is known to increase the proliferation of
monocyte progenitors, therefore GPCMV-MIP may enhance the proliferation
and/or recruitment of permissive cells consistent with the role of MCK2 (Haggerty
and Schleiss, 2002).
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VIII. Chemokine Receptor Homologs
In addition to viral chemokine homologs, CMVs encode proteins with
homology to chemokine receptors (Chee et al., 1990). Chemokine receptors are
members of the G-protein coupled receptor (GPCR) family (Murphy, 1994). The
four chemokine receptor homologs encoded by the cytomegaloviruses have
homology to the CC chemokine receptor family. Two genes, UL33 and UL78, are
conserved among all sequenced CMVs, while primate CMVs encode two
additional GPCRs, US27 and US28 (van Cleef et al., 2006).
The US28 encoded protein (pUS28) is the best characterized of the
GPCR homologs. US28 has the highest sequence homology to the cellular
receptor, CCR1, and binds a number of CC chemokines including CCL5
(RANTES), CCL2 (MCP-1), CCL3 (MIP-1), and CCL4 (MIP-1) (Gao and
Murphy, 1994; Kuhn, Beall, and Kolattukudy, 1995). Interestingly, pUS28 binds
with highest affinity to the CX3C chemokine, CX3CL1 (fractalkine) (Kledal,
Rosenkilde, and Schwartz, 1998). Upon binding, pUS28 induces chemokine
internalization, removing chemokines from the extracellular environment
(Bodaghi et al., 1998; Michelson et al., 1997; Vieira et al., 1998). Consistently,
pUS28 inhibits monocyte migration in vitro and media from infected monolayers
lack CCL5 and CCL2, which are present in media of untreated cells (RandolphHabecker et al., 2002). Constitutive endocytosis and recycling of pUS28
contributes to chemokine internalization however chemokine binding is not
sufficient to induce constitutive endocytosis of pUS28 (Fraile-Ramos et al.,
2001). By acting as a “chemokine sink”, pUS28 could alter or inhibit chemokine194

dependent immune responses. The related chemokine homolog, pUS27, also
shows some ability to internalize chemokines (Bodaghi et al., 1998; Margulies
and Gibson, 2007), indicating the important function of these viral GPCRs.
pUS28 elicits ligand-dependent signaling, triggering calcium mobilization
upon binding to CCL5, CCL2, CCL3 and CCL7. pUS28 ulitilizes the G proteins
Gi and G16 to mediate calcium mobilization upon binding of CCL5 or CCL7
(Billstrom et al., 1998; Casarosa et al., 2001; Gao and Murphy, 1994).
Interestingly, G16 expression is restricted to hematopoietic cells (Wilkie et al.,
1991). Since CMV has a tropism for many cells of this lineage, pUS28 may alter
G16 signaling in these cells to benefit the CMV life cycle. pUS28 also induces
agonist-dependent migration of smooth muscle cells (SMCs). Migration of SMCs
in response to pUS28 requires the protein tyrosine kinase (PTK) pathway,
indicating pUS28 activates a number of cellular pathways in vitro (Streblow et al.,
1999). As with many CMV proteins, the effects of pUS28 vary depending on the
system and cell types analyzed.
Like the Kaposi’s sarcoma-associated herpesvirus (KSHV) GPCR
homolog ORF74 (McLean et al., 2004), pUS28 can constitutively activate several
signaling pathways, including phospholipase C (PLC), NFB, NFAT, and cAMPresponsive element (CRE)-dependent pathways (Casarosa et al., 2001; FraileRamos et al., 2001; McLean et al., 2004; Miller et al., 2003; Stropes and Miller,
2008; Waldhoer et al., 2002). CC chemokines do not enhance signaling,
although CX3CL1 acts as a partial inverse agonist, decreasing the levels of
pUS28 constitutive activity (Casarosa et al., 2001; Waldhoer et al., 2002).
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Interestingly, the constitutive endocytosis of pUS28 occurs independently of its
constitutive signaling and different domains of pUS28 control these two
phenomenon (Fraile-Ramos et al., 2001). However, the constitutive signaling of
pUS28 contributes to the induction of caspase-dependent cell death in vitro
(Pleskoff et al., 2005). Furthermore, pUS28 can induce transformation of NIH3T3
cells and promote tumor formation in nude mice. Mice inoculated with cells
expressing a mutated pUS28 that lacks constitutive activity show attenuated
tumor formation demonstrating the importance of constitutive signaling in pUS28mediated tumor formation (Maussang et al., 2006).
Despite extensive research on the function of pUS28, its role in CMV
pathogenesis in vivo is still unknown. pUS28 may alter the immune response by
sequestering host chemokines or activate signaling pathways that contribute to
viral replication or spread. pUS28-induced SMC migration may play a role in the
accelerated vascular disease associated with HCMV (Melnick, Adam, and
Debakey, 1993; Zhou et al., 1996). Since HCMV has been identified in certain
cancers (Cobbs et al., 2002; Harkins et al., 2002), pUS28 may contribute to
tumor formation in these individuals.
The UL33 gene is conserved in all  herpesviruses, including HCMV
(UL33), RCMV (R33), and MCMV (M33). While no ligands have been identified
for either pUL33 or pR33, pM33 is activated by CCL5 (Melnychuk et al., 2005).
All three viral proteins show constitutive activity, although they differentially
activate specific signaling pathways (Casarosa et al., 2003; Gruijthuijsen et al.,
2002; Sherrill and Miller, 2006; Waldhoer et al., 2002). While not essential for
196

viral replication in vitro, both pR33 and pM33 are important for replication of CMV
in the salivary gland (Beisser et al., 1998; Davis-Poynter et al., 1997; Margulies,
Browne, and Gibson, 1996). In MCMV, this defect was linked to the constitutive
activity of pM33 (Case et al., 2008) and illustrates the importance of constitutive
signaling in vivo. Like pUS28, pM33 and pR33 induce SMC migration (Melnychuk
et al., 2005; Streblow et al., 2005). Taken together, this suggests GPCRs of the
UL33 family alter cellular trafficking during CMV infection, which may contribute
to viral pathogenesis.
UL78 gene family encoded proteins have only limited homology to known
chemokine receptors (van Cleef et al., 2006). Nevertheless, this gene is
conserved in all  herpesviruses suggesting they have some role in the life cycle
of herpesviruses. The UL78 proteins of MCMV and RCMV, pM78 and pR78,
respectively, are important for viral replication in vitro and in vivo (Beisser et al.,
1999; Kaptein et al., 2003; Oliveira and Shenk, 2001). The HCMV homolog,
pUL78, is not required for replication of HCMV in vitro (Michel et al., 2005) thus
MCMV and RCMV may be more dependent on its function for viral replication.
Although, members of the UL78 family are clearly important for viral replication
for some CMVs, data regarding their specific function as GPCRs is not currently
available.
IX. Viral Chemokine Binding Proteins
Chemokine binding proteins (CBPs) are virally encoded secreted proteins
that competively bind chemokines and interfere with their interactions with
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cellular receptors. Unlike viral chemokine and chemokine receptor homologs,
which were likely acquired from the host, CBPs generally show no homology to
known proteins and homology of these proteins across among viruses is not
conserved (Seet and McFadden, 2002). Until recently, no CMV species was
known to encode a CBP. However, a HCMV encoded protein, p21.5, has been
identified with chemokine binding properties. mRNA transcripts of the gene
UL21.5 are packaged in the HCMV virion and thus may function soon after viral
entry into the cell. Although many CBPs interact with multiple chemokines (Lalani
and McFadden, 1997), p21.5 is unusual in that it selectively binds CCL5
(RANTES) in vitro blocking the interaction of the chemokine with its cellular
receptors (Lalani and McFadden, 1997; Wang, Bresnahan, and Shenk, 2004).
No data is available which evaluates the ability of p21.5 to interfere with CCL5
function in vivo and its effect on viral survival.
X. Apoptosis
Apoptosis is a mechanism for programmed cell death that plays an
important role in the elimination of cells during development and virally infected
cells as part of the host’s innate immunity (O'Brien, 1998; Vaux and Korsmeyer,
1999). Many viruses including CMVs have strategies to prevent apoptosis
(Mocarski, 2002). HCMV encodes two proteins in particular that directly interfere
with the apoptosis pathway. The HCMV UL36 gene encodes a viral inhibitor of
caspase-8 induced apoptosis (vICA) and exon 1 of UL37 encodes the viral
mitochondrial inhibitor of apoptosis (vMIA) (Goldmacher, 2005).
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vICA protects cells in vitro from extrinsic apoptosis mediated through
ligation of the death receptors, Fas and TNFR-1 (Skaletskaya et al., 2001). vICA
is a virion constituent (Patterson and Shenk, 1999) and inhibits apoptosis soon
after HCMV enters the cell. vICA inhibits caspase-8 activation by interacting with
the proenzyme, procaspase-8 (Skaletskaya et al., 2001). vICA prevents the
interaction of procaspase-8

with the adapter protein, Fas-associated death

domain (FADD), which inhibits the processing of procaspase-8 to its active form
(Andoniou and Degli-Esposti, 2006). Therefore, vICA is functionally similar,
although mechanistically distinct from, cellular and viral FLICE inhibitory proteins
(FLIPS), which also interfere with caspase-8 activation (Thome et al., 1997).
However, vICA has no homology with any identified FLIPs.
vICA is dispensable for replication and some HCMV lab strains have
inactivating mutations in the UL36 gene (Patterson and Shenk, 1999;
Skaletskaya et al., 2001). Nevertheless, vICA homologs are conserved in the
genomes of all sequenced -herpesviruses except for guinea pig CMV (GPCMV)
where no positional homolog has been identified (Goldmacher, 2005). The vICA
homologs of RhCMV and MCMV, Rh36 and M36, respectively, also have
antiapoptotic activities in vitro (McCormick et al., 2003). Therefore, vICA may
have a conserved function in the life cycle of these viruses.
In contrast to vICA, vMIA protects cells from intrinsic apoptosis induced
following

damage

to

the

mitochondrial membrane (Goldmacher, 2002;

Goldmacher et al., 1999; McCormick et al., 2005). vMIA only blocks Fasmediated apoptosis in cells in which apoptosis proceeds through a mitochondrial199

dependent step (Skaletskaya et al., 2001). vMIA has not been identified in virion
particles and inhibits apoptosis at later times compared to vICA consistent with a
requirement for transcription of vMIA following viral entry into the cell
(Goldmacher, 2002). vMIA function requires localization at the mitochondria
where it induces structural changes and inhibits mitochondrial release of
cytochrome c, blocking downstream events in the apoptosis pathway
(Goldmacher et al., 1999). vMIA was initially shown to interact with adenine
nucleotide translocator (ANT), a protein involved in regulating permeability of the
mitochondrial membrane (Arnoult et al., 2004; Goldmacher et al., 1999).
However, binding of this protein does not correlate with vMIA function and is
likely a nonspecific interaction (Arnoult et al., 2004). vMIA also binds the
proapoptotic protein, Bax, inducing aggregation of Bax molecules at the
mitochodrial membrane preventing membrane permeabilization (Poncet et al.,
2004). The screening of proteins that interact with the antiapoptotic domain of
vMIA identified the protein growth arrest and DNA damage 45 (GADD45).
GADD45 enhances vMIA-induced apoptosis possibly protecting it from
proteasomal degradation (Smith and Mocarski, 2005). Sequence homologs of
vMIA have only been found in primate CMVs (McCormick et al., 2003). However
a recently identified gene product in MCMV, m38.5, was shown to interact with
Bax and inhibit apoptosis (McCormick et al., 2005; Norris and Youle, 2008).
Therefore, vMIA functional homologs may exist in other cytomegaloviruses.
The MCMV protein encoded by M45 has no homology to known apoptosis
inhibitors but was recently shown to supress the cell death pathway in a manner
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unique to viral inhibitors of apoptosis (Brune et al., 2001). M45 interacts with the
receptor-interacting protein kinase I (RIPI) via a RIP homotypic interaction motif
(RHIM). By binding to RIP, M45 intereferes with signaling via cell death receptors
protecting virus infected cells from apoptosis (Upton, Kaiser, and Mocarski,
2008).

Adaptive Immune Response
XI. T Cell Mediated Immunity
T cell mediated immune responses, particularly CD8+ T cell dependent
responses, are integral to the clearance of cytomegalovirus infections (Edward S.
Mocarski, 2007). Cytomegaloviruses impair T cell activation by interfering with
both MHC class I and II antigen processing and presentation. Although this has
been shown in vitro, Th or CTL responses are generated during CMV infection in
vivo (Alcami and Koszinowski, 2000; Hengel et al., 1999; Khan et al., 2004a;
Trzonkowski et al., 2003).
The US region of the HCMV genome encodes a number of endoplasmic
reticulum (ER) resident glycoproteins that alter MHC expression (Jones et al.,
1995). The first of these proteins to be expressed following HCMV infection is the
US3 encoded immediate early protein, gpUS3, which likely interferes with T cell
recognition early during viral replication (del Val et al., 1992; Thrower et al.,
1996). gpUS3 binds MHC I molecules and retains them in the ER, inhibiting
antigen presentation to CD8+ T cells (Ahn et al., 1996; Jones et al., 1996; Jun et
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al., 2000). The transmembrane domains of gpUS3 are responsible for binding
MHC I (Lee et al., 2000; Zhao and Biegalke, 2003), however, luminal regions of
gpUS3 are needed for retention of MHC in the ER (Lee, Park, and Ahn, 2003;
Lee et al., 2000; Misaghi et al., 2004; Zhao and Biegalke, 2003). Interestingly,
gpUS3 also binds tapasin and this interaction prevents tapasin-mediated protein
loading of MHC I molecules. Therefore, gpUS3 only retains MHC I alleles that
are tapasin dependent (Park et al., 2004). An alternatively spiced form of gpUS3
competively binds tapasin and may represent a regulatory mechanism for gpUS3
activity (Shin et al., 2006). gpUS3 also binds and downregulates MHC II which
subsequently decreases antigen presentation to CD4+ T cells. However, this
interaction is not as well characterized as that of gpUS3 with MHC I molecules
(Hegde et al., 2002).
In contrast to gpUS3, the binding of MHC I molecules to the US2 and
US11 encoded HCMV proteins, gpUS2 and gpUS11, respectively, leads to the
rapid degradation of MHC I molecules (Wiertz et al., 1996a; Wiertz et al., 1996b).
Both proteins bind MHC I molecules resulting in their removal from the ER to the
cytosol where they undergo proteasome-dependent degradation (Ahn et al.,
1996; Wiertz et al., 1996a; Wiertz et al., 1996b). This process requires a
functional ubiquitination system although only gpUS2 specifically depends on
MHC I ubiquitination for protein degradation (Hassink et al., 2006; Kikkert et al.,
2001; Shamu et al., 1999). In addition to the ubiquitin system, gpUS2 and
gpUS11 associate with other cellular proteins that facilitate recognition and
removal of proteins via the endoplasmic reticulum associated protein degradation
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(ERAD) pathway (Shamu et al., 2001; Tirosh et al., 2005). gpUS2 forms a
complex with the chaperones, calnexin, BiP, and calreticulin to mediate MHC I
degradation (Oresic and Tortorella, 2008). In contrast, gpUS11-dependent
protein degradation requires Derlin-1, a protein that plays a role in the removal of
misfolded proteins (Lilley and Ploegh, 2004).
Why HCMV encodes two different proteins that target MHC I for
degradation is unclear. gpUS2 and gpUS11 differ in their specificities for MHC I
alleles. While they may overlap in function, they likely mediate distinct effects on
MHC I expression (Machold et al., 1997). This difference in specificity is likely the
result of different binding requirements for gpUS2 and gpUS11. The luminal
portion of gpUS2 interacts with residues in the 2/3 region of the luminal domain
of MHC I molecules (Gewurz et al., 2001a; Gewurz et al., 2001b). Specifically,
gpUS2-mediated degradation requires the presence of an arginine at residue 181
of MHC I molecules. However, this residue is not sufficient for degradation of
some MHC I alleles and other residues must be important for these molecules
(Thilo et al., 2006). The luminal region of gpUS11 is also important for MHC I
binding, however, gpUS11 interacts with residues in the 1/2 domain of MHC I
molecules (Barel et al., 2003; Lee et al., 2005). Additionally, gpUS2, but not
gpUS11, interferes with CD4+ T cell recognition by downregulating MHC II
molecules in a number of different cell types in vitro (Hegde and Johnson, 2003;
Hegde et al., 2002; Tomazin et al., 1999).
The HCMV US6 gene, encodes another glycoprotein, gpUS6, that
downregulates MHC I expression (Ahn et al., 1997; Hengel et al., 1997; Lehner
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et al., 1997). Like the other US proteins that interfere with MHC I expression,
gpUS6 mediates retention of MHC I via its luminal domain (Ahn and Hayward,
1997). However, the gpUS6 mechanism is unique in that it binds to TAP-1 and
TAP-2 heterodimers (Halenius et al., 2006) in the transporter associated with
antigen processing (TAP) complex (Hengel et al., 1997; Kyritsis et al., 2001;
Lehner et al., 1997). Through its association with TAP, gpUS6 prevents the
binding of ATP to TAP (Hewitt, Gupta, and Lehner, 2001) and subsequent TAP
peptide translocation (Ahn et al., 1997; Hengel et al., 1997). gpUS6 expression is
solely responsible for the inhibition of TAP in HCMV infected cells (Hengel et al.,
1996) and downregulates all MHC I alleles tested (Llano et al., 2003). In addition
to impairing CD8+ T cell responses, this decrease in MHC I expression also
makes infected cells susceptible to NK cell cytotoxicity (Llano et al., 2003), which
may explain why CMVs have evolved mechanisms for preventing NK lysis (see
section IV).
Two additional HCMV encoded proteins, gpUS8 and gpUS10, bind MHC I
molecules. However, neither protein downregulates cell surface MHC I
expression, although gpUS10 slows MHC I maturation and egress from the ER.
The function of these proteins in HCMV infection is currently unknown (Furman
et al., 2002; Tirabassi and Ploegh, 2002).
Other cytomegaloviruses have homologs of some of the HCMV US family
members. CCMV encodes a gpUS6 homolog that binds TAP. However, this
interaction doesn’t downregulate MHC I expression in chimpanzee cells in vitro,
making the function of this homolog unclear (Dugan and Hewitt, 2008). In
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contrast, RhCMV encodes homologs of gpUS2, gpUS3, gpUS6, and gpUS11
(Hansen et al., 2003). Each of the RhCMV proteins functions similarly to its
HCMV counterpart (Pande et al., 2005). Therefore, RhCMV may be a valuable
model system for analyzing the function of these proteins during CMV infection in
vivo.
MCMV encodes three proteins unrelated to those of HCMV that interfere
with MHC I expression in infected cells. gp48, gp40, and gp34 are encoded by
m6, m152, and m4, respectively. Both gp40 and gp48 inhibit antigen presentation
to CD8+ T cells in vitro (Reusch et al., 1999; Ziegler et al., 1997). gp40 and gp48
bind MHC I molecules and retain them intracellularly (Krmpotic et al., 1999;
Reusch et al., 1999; Ziegler et al., 1997), although each protein does so via
different mechanisms. gp40 retains MHC I molecules in the ER-Golgi
intermediate compartment (ERGIC)-cis golgi network (Ziegler et al., 1997)
whereas gp48 binds to MHC I molecules and targets them to lysosomes for
degradation (Reusch et al., 1999). Deletion of m152 restores MHC expression in
MCMV infected cells suggesting gp40 is the main regulator of MHC I
downregulation (Holtappels et al., 2006; Kavanagh et al., 2001). However, gp48
cooperates with gp40 to enhance MHC I retention in vitro (Wagner et al., 2002).
gp48 and gp40 also show different specificities for MHC I alleles and thus are
both required for efficient class I downregulation in certain cell types (Hengel et
al., 2000; LoPiccolo et al., 2003). Surprisingly, the presence of m152 does not
impact the CTL response in mice based on studies using recombinant MCMVs.
Therefore, the in vivo role of m152 as well as m4 and m6 is not clear (Gold et al.,
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2002; Munks et al., 2007; Pinto et al., 2006). One possible explanation for this
lack of CTL alteration in vivo is cross-priming of CD8+ T cells by uninfected
antigen presenting cells (APCs), which could circumvent function of gp40 in mice
(Munks et al., 2007).
The MCMV protein gp34 also associates with MHC I molecules (Kleijnen
et al., 1997; Lu, Kavanagh, and Hill, 2006). In contrast to gp40 and gp48, gp34
can decrease the intracellular retention of MHC I molecules (Kleijnen et al., 1997;
Wagner et al., 2002). However, this phenomenon is seen only in the absence of
m6 (gp48) suggesting gp48 expression may antagonize the function of gp34 and
provide a mechanism to regulate the extent of MHC I expression in infected cells
(Holtappels et al., 2006; Wagner et al., 2002).

Conclusion
It is clear based on the numerous viral proteins that respond to the host’s
denfese mechanisms that the relationship of the cytomegaloviruses with their
hosts is complex. CMVs can influence the magnitude and quality of both innate
and adaptive immune responses. Despite this the host still launches a robust
immune response to CMV but not before the virus establishes latency within the
host. Therefore CMV infection does not eliminate host immunity but modulates it
to allow survival of both the virus and the host, as both are important to the life
cycle of the virus.

206

Vita
Mindy Miller-Kittrell was born July 21, 1977 in Franklin, TN. She graduated
from Franklin High School in 1995. She attended Middle Tennessee State
University in Murfreesboro, TN where she received her B.A. in Chemistry and
Microbiology. She began her graduate studies at the University of TennesseeKnoxville in August 2002. She graduated with a Doctor of Philosophy in
Microbiology in the summer of 2008.

207

